Global Neuroprotection Drugs Market By Drugs Type (Antidepressants, Antiepileptic, Antipsychotic, Anti-inflammatory, Anesthetics, Antagonists, Antibiotics, Antidepressants, Antioxidants, Cytokines, Ion Channel Blockers, Neurosteroids, Nutraceuticals, Pathway Inhibitors and Others (Vaccines, Toxins, etc.)), By Application (Cerebrovascular Disease (Ischemic Stroke, Hemorrhagic Stroke, cerebrovascular anomalies(intracranial aneurysms and arteriovenous malformations), Neurodegenerative Disorders (Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease (HD), Amyotrophic Lateral Sclerosis, Progressive supranuclear palsy (PSP), Corticobasal Degeneration (CBD), Frontotemporal Dementia (FTD), Dementia With Lewy Bodies (DLB) Others (Multiple System Atrophy (MSA), Chronic Traumatic Encephalopathy (CTE), Etc.), Traumatic CNS Injuries (Coup-Contrecoup Brain Injury, Concussion, Brain Concussion, Diffuse Axonal Injury, Penetrating Injury, Second Impact Syndrome, Others); By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 – 2027
Industry Trends
Global Neuroprotection drugs market was valued at US$ 28,908.7 million in 2018 and is estimated to reach US$ 33,481.7 million by 2027, growing at an estimated CAGR of 1.56 % over the next eight years. Rising incidences of cerebral stroke and other severe disorders such as Alzheimer’s disease, epilepsy, and Parkinsonism is expected to fuel demand of neuroprotective drugs market thereby driving the overall neuroscience industry growth. Strokes are the major cause of distress in the industrialized countries and ischemic stroke is one of the greatest causes for disability. An ischemic stroke happens when a cerebral vessel impedes, obstructing streaming of blood to a portion of the brain. With a maturing populace, putative medicines for ischemic stroke are required to constrain the degree of stroke-actuated dismalness and mortality. Parkinson’s disease (PD) and Alzheimer's disease (AD) are extreme neurodegenerative disorders. Neuroprotective drugs will be required for the treatment of these strokes and disorders. Moreover, neuroprotection drugs such as erythropoietin (EPO) have the potential to reduce generalized brain injury caused commonly by brain tumor treatment. Such incidences and its successive factors is anticipated to propel the global neuroprotection drugs market over the forecast period.
Neuroprotection, mainly referred as the “protection of neurons” is a type of medication defined as an effect that may result in salvage, recovery or regeneration of the nervous system, its cell, structure and function. Neuroprotection drugs also protects the brain from secondary injury in the immediate period of trauma.
Failure of drug delivery is one of the major restraints in the global neuroprotection drugs market. Drugs travelling in the bloodstream may be unable to reach the targeted area of the cerebrum, either because of poor perfusion of ischemic tissues or inability to cross the blood–brain barrier. Furthermore, side effects of specific drugs can counteract administration of successful dosages that are proportional to those utilized in preclinical studies.
A class of novel cyclic dipeptides (diketopiperazines), structurally like a physiologically dynamic metabolic result of thyrotropin-releasing hormone, have appeared in neuronal cell cultures against oxygen and/or glucose hardship, free radical damage, excitotoxicity, mechanical injury, and various proapoptotic and pronecrotic affronts, likewise extraordinarily lessening sore volume and improving motor and cognitive results over numerous species and models of brain injury.
By drug type, antidepressants has the highest penetration in 2018 and is expected continue the same trend over the forecast period. Antidepressants are an important category of neuroprotection drugs market that can help relieve indications of anxiety disorders, depression, dysthymia, or mild chronic depression, and other such conditions. The primary objective of antidepressants is to correct chemical imbalances of neurotransmitters in the cerebrum that are responsible for changes in one's mood and behavior. Chemical antidepressants mostly include monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and selective norepinephrine reuptake inhibitors (SNRIs). Therapeutic applications received from the same can be felt immediately or in some cases, it is observed after few days or often not until 3 weeks. Nonchemical antidepressants such as electroconvulsive therapy (ECT) and physical exercise are some ways that tend to employ similar therapeutic mechanisms.
Neurodegenerative disorders segment exhibited the largest share in 2018, accounting for more than 60% of the global neuroprotection drugs market. Neurodegenerative disorders are caused by the dynamic demise of neurons in various regions of the brain. The dynamic loss of nerve cells is what gives rise to the neurological and neuropsychological signs and symptoms for each of these diseases. Neurodegenerative disorders affect a large number of individuals around the world, the most common types being Alzheimer's disease and Parkinson's disease. A drug named Selegiline, discovered by Cardinal Health Inc, is a neuroprotectant can be use for disease indications such as cerebrovascular ischemia and Parkinson’s disease.
Europe had the largest market share for the year 2018 that accounted over 30% of the overall neuroprotection drugs market. In a recent study by European public assessment report (EPAR), the established efficacy result achieved by Mirapexin has been reported. It is available as immediate release white tablets and prolonged release white tablets. The same is used to treat symptoms of Parkinson’s disease. The medication can be either used solely or can be used in combination with levodopa. The starting dose is either one 0.088-mg immediate-release tablet thrice a day or one 0.26-mg prolonged-release tablet, only one time per day. The dose should be increased every six to seven days until the symptoms are controlled. This should also be associated without causing side effects. It is less effective for patients suffering from kidney diseases.
North America, Neuroprotection Drugs Market Revenue & Forecast, (US$ Million), 2015 – 2027
Competitive Landscape
The report provides both, qualitative and quantitative research of patient recliners market, market, as well as provides comprehensive insights and favored development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings, specification, pricing, and gross margin.
Some of the players operating in the neuroprotection drugs market are F. Hoffmann-La Roche Ltd., Genervon Biopharmaceuticals LLC, Bionure Farma S.L., Biogen, Inc., Astrocyte Pharmaceuticals, Inc., AstraZeneca PLC, Neuren Pharmaceuticals Ltd., Novartis Pharmaceuticals Corporation, Teva Pharmaceutical Industries Ltd. amongst others.
Neuroprotection Drugs Market:
- By Drugs Type
- Anesthetics
- Antagonists
- Antibiotics
- Antidepressants
- Antiepileptic agents
- Anti-inflammatory agents
- Antioxidants/free radical scavengers
- Cytokines
- Ion Channel Blockers
- Neurosteroids
- Nutraceuticals
- Pathway Inhibitor
- Others (Vaccines, Toxins, etc.)
- By Application
- Cerebrovascular Disease
- ischemic stroke
- hemorrhagic stroke
- cerebrovascular anomalies
- intracranial aneurysms
- arteriovenous malformations
- Neurodegenerative Disorders
- Alzheimer’s Disease
- Parkinson’s Disease
- Amyotrophic Lateral Sclerosis
- Progressive supranuclear palsy (PSP)
- Corticobasal Degeneration (CBD)
- Frontotemporal Dementia (FTD)
- Dementia With Lewy Bodies (DLB)
- Huntington’s Disease (HD)
- Others (multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
- Traumatic CNS Injuries
- Coup-Contrecoup Brain Injury
- Concussion
- Brain Contusion
- Diffuse Axonal Injury
- Penetrating Injury
- Second Impact Syndrome
- Others
- Others
- Cerebrovascular Disease
- By Geography
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Benelux Union
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- New Zealand
- Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- GCC Countries
- Southern Africa
- Rest of Middle East and Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2013 - 2017
1.2.2. Base
Year: 2018
1.2.3. Forecast
Years: 2019 – 2027
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Neuroprotection Drugs Market
6. Market Synopsis:
Neuroprotection Drugs Market
7. Neuroprotection Drugs Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in
Neuroprotection Drugs Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Neuroprotection Drugs Market
7.6. Porter’s
Five Force Analysis
8. Global Neuroprotection Drugs Market Analysis and Forecasts,
2019 – 2027
8.1. Overview
8.1.1. Global
Neuroprotection Drugs Market Revenue (US$ Mn)
8.2. Global
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type
8.2.1. Anesthetics
8.2.1.1. Definition
8.2.1.2. Market
Penetration, 2018
8.2.1.3. Market
Estimation, 2013 – 2018
8.2.1.4. Market
Forecast, 2019 – 2027
8.2.1.5. Compound
Annual Growth Rate (CAGR)
8.2.1.6. Regional
Bifurcation
8.2.1.6.1. North
America
8.2.1.6.1.1. Market
Estimation, 2013 – 2018
8.2.1.6.1.2. Market
Forecast, 2019 – 2027
8.2.1.6.2. Europe
8.2.1.6.2.1. Market
Estimation, 2013 – 2018
8.2.1.6.2.2. Market
Forecast, 2019 – 2027
8.2.1.6.3. Asia
Pacific
8.2.1.6.3.1. Market
Estimation, 2013 – 2018
8.2.1.6.3.2. Market
Forecast, 2019 – 2027
8.2.1.6.4. Middle
East and Africa
8.2.1.6.4.1. Market
Estimation, 2013 – 2018
8.2.1.6.4.2. Market
Forecast, 2019 – 2027
8.2.1.6.5. Latin
America
8.2.1.6.5.1. Market
Estimation, 2013 – 2018
8.2.1.6.5.2. Market
Forecast, 2019 – 2027
8.2.2. Antagonists
8.2.2.1. Definition
8.2.2.2. Market
Penetration, 2018
8.2.2.3. Market
Estimation, 2013 – 2018
8.2.2.4. Market
Forecast, 2019 – 2027
8.2.2.5. Compound
Annual Growth Rate (CAGR)
8.2.2.6. Regional
Bifurcation
8.2.2.6.1. North
America
8.2.2.6.1.1. Market
Estimation, 2013 – 2018
8.2.2.6.1.2. Market
Forecast, 2019 – 2027
8.2.2.6.2. Europe
8.2.2.6.2.1. Market
Estimation, 2013 – 2018
8.2.2.6.2.2. Market
Forecast, 2019 – 2027
8.2.2.6.3. Asia
Pacific
8.2.2.6.3.1. Market
Estimation, 2013 – 2018
8.2.2.6.3.2. Market
Forecast, 2019 – 2027
8.2.2.6.4. Middle
East and Africa
8.2.2.6.4.1. Market
Estimation, 2013 – 2018
8.2.2.6.4.2. Market
Forecast, 2019 – 2027
8.2.2.6.5. Latin
America
8.2.2.6.5.1. Market
Estimation, 2013 – 2018
8.2.2.6.5.2. Market
Forecast, 2019 – 2027
8.2.3. Antibiotics
8.2.3.1. Definition
8.2.3.2. Market
Penetration, 2018
8.2.3.3. Market
Estimation, 2013 – 2018
8.2.3.4. Market
Forecast, 2019 – 2027
8.2.3.5. Compound
Annual Growth Rate (CAGR)
8.2.3.6. Regional
Bifurcation
8.2.3.6.1. North
America
8.2.3.6.1.1. Market
Estimation, 2013 – 2018
8.2.3.6.1.2. Market
Forecast, 2019 – 2027
8.2.3.6.2. Europe
8.2.3.6.2.1. Market
Estimation, 2013 – 2018
8.2.3.6.2.2. Market
Forecast, 2019 – 2027
8.2.3.6.3. Asia
Pacific
8.2.3.6.3.1. Market
Estimation, 2013 – 2018
8.2.3.6.3.2. Market
Forecast, 2019 – 2027
8.2.3.6.4. Middle
East and Africa
8.2.3.6.4.1. Market
Estimation, 2013 – 2018
8.2.3.6.4.2. Market
Forecast, 2019 – 2027
8.2.3.6.5. Latin
America
8.2.3.6.5.1. Market
Estimation, 2013 – 2018
8.2.3.6.5.2. Market
Forecast, 2019 – 2027
8.2.4. Antidepressants
8.2.4.1. Definition
8.2.4.2. Market
Penetration, 2018
8.2.4.3. Market
Estimation, 2013 – 2018
8.2.4.4. Market
Forecast, 2019 – 2027
8.2.4.5. Compound
Annual Growth Rate (CAGR)
8.2.4.6. Regional
Bifurcation
8.2.4.6.1. North
America
8.2.4.6.1.1. Market
Estimation, 2013 – 2018
8.2.4.6.1.2. Market
Forecast, 2019 – 2027
8.2.4.6.2. Europe
8.2.4.6.2.1. Market
Estimation, 2013 – 2018
8.2.4.6.2.2. Market
Forecast, 2019 – 2027
8.2.4.6.3. Asia
Pacific
8.2.4.6.3.1. Market
Estimation, 2013 – 2018
8.2.4.6.3.2. Market
Forecast, 2019 – 2027
8.2.4.6.4. Middle
East and Africa
8.2.4.6.4.1. Market
Estimation, 2013 – 2018
8.2.4.6.4.2. Market
Forecast, 2019 – 2027
8.2.4.6.5. Latin
America
8.2.4.6.5.1. Market
Estimation, 2013 – 2018
8.2.4.6.5.2. Market
Forecast, 2019 – 2027
8.2.5. Antiepileptic
agents
8.2.5.1. Definition
8.2.5.2. Market
Penetration, 2018
8.2.5.3. Market
Estimation, 2013 – 2018
8.2.5.4. Market
Forecast, 2019 – 2027
8.2.5.5. Compound
Annual Growth Rate (CAGR)
8.2.5.6. Regional
Bifurcation
8.2.5.6.1. North
America
8.2.5.6.1.1. Market
Estimation, 2013 – 2018
8.2.5.6.1.2. Market
Forecast, 2019 – 2027
8.2.5.6.2. Europe
8.2.5.6.2.1. Market
Estimation, 2013 – 2018
8.2.5.6.2.2. Market
Forecast, 2019 – 2027
8.2.5.6.3. Asia
Pacific
8.2.5.6.3.1. Market
Estimation, 2013 – 2018
8.2.5.6.3.2. Market
Forecast, 2019 – 2027
8.2.5.6.4. Middle
East and Africa
8.2.5.6.4.1. Market
Estimation, 2013 – 2018
8.2.5.6.4.2. Market
Forecast, 2019 – 2027
8.2.5.6.5. Latin
America
8.2.5.6.5.1. Market
Estimation, 2013 – 2018
8.2.5.6.5.2. Market
Forecast, 2019 – 2027
8.2.6. Anti-inflammatory
agents
8.2.6.1. Definition
8.2.6.2. Market
Penetration, 2018
8.2.6.3. Market
Estimation, 2013 – 2018
8.2.6.4. Market
Forecast, 2019 – 2027
8.2.6.5. Compound
Annual Growth Rate (CAGR)
8.2.6.6. Regional
Bifurcation
8.2.6.6.1. North
America
8.2.6.6.1.1. Market
Estimation, 2013 – 2018
8.2.6.6.1.2. Market
Forecast, 2019 – 2027
8.2.6.6.2. Europe
8.2.6.6.2.1. Market
Estimation, 2013 – 2018
8.2.6.6.2.2. Market
Forecast, 2019 – 2027
8.2.6.6.3. Asia
Pacific
8.2.6.6.3.1. Market
Estimation, 2013 – 2018
8.2.6.6.3.2. Market
Forecast, 2019 – 2027
8.2.6.6.4. Middle
East and Africa
8.2.6.6.4.1. Market
Estimation, 2013 – 2018
8.2.6.6.4.2. Market
Forecast, 2019 – 2027
8.2.6.6.5. Latin
America
8.2.6.6.5.1. Market
Estimation, 2013 – 2018
8.2.6.6.5.2. Market
Forecast, 2019 – 2027
8.2.7. Antioxidants/free
radical scavengers
8.2.7.1. Definition
8.2.7.2. Market
Penetration, 2018
8.2.7.3. Market
Estimation, 2013 – 2018
8.2.7.4. Market
Forecast, 2019 – 2027
8.2.7.5. Compound
Annual Growth Rate (CAGR)
8.2.7.6. Regional
Bifurcation
8.2.7.6.1. North
America
8.2.7.6.1.1. Market
Estimation, 2013 – 2018
8.2.7.6.1.2. Market
Forecast, 2019 – 2027
8.2.7.6.2. Europe
8.2.7.6.2.1. Market
Estimation, 2013 – 2018
8.2.7.6.2.2. Market
Forecast, 2019 – 2027
8.2.7.6.3. Asia
Pacific
8.2.7.6.3.1. Market
Estimation, 2013 – 2018
8.2.7.6.3.2. Market
Forecast, 2019 – 2027
8.2.7.6.4. Middle
East and Africa
8.2.7.6.4.1. Market
Estimation, 2013 – 2018
8.2.7.6.4.2. Market
Forecast, 2019 – 2027
8.2.7.6.5. Latin
America
8.2.7.6.5.1. Market
Estimation, 2013 – 2018
8.2.7.6.5.2. Market
Forecast, 2019 – 2027
8.2.8. Cytokines
8.2.8.1. Definition
8.2.8.2. Market
Penetration, 2018
8.2.8.3. Market
Estimation, 2013 – 2018
8.2.8.4. Market
Forecast, 2019 – 2027
8.2.8.5. Compound
Annual Growth Rate (CAGR)
8.2.8.6. Regional
Bifurcation
8.2.8.6.1. North
America
8.2.8.6.1.1. Market
Estimation, 2013 – 2018
8.2.8.6.1.2. Market
Forecast, 2019 – 2027
8.2.8.6.2. Europe
8.2.8.6.2.1. Market
Estimation, 2013 – 2018
8.2.8.6.2.2. Market
Forecast, 2019 – 2027
8.2.8.6.3. Asia
Pacific
8.2.8.6.3.1. Market
Estimation, 2013 – 2018
8.2.8.6.3.2. Market
Forecast, 2019 – 2027
8.2.8.6.4. Middle
East and Africa
8.2.8.6.4.1. Market
Estimation, 2013 – 2018
8.2.8.6.4.2. Market
Forecast, 2019 – 2027
8.2.8.6.5. Latin
America
8.2.8.6.5.1. Market
Estimation, 2013 – 2018
8.2.8.6.5.2. Market
Forecast, 2019 – 2027
8.2.9. Ion
Channel Blockers
8.2.9.1. Definition
8.2.9.2. Market
Penetration, 2018
8.2.9.3. Market
Estimation, 2013 – 2018
8.2.9.4. Market
Forecast, 2019 – 2027
8.2.9.5. Compound
Annual Growth Rate (CAGR)
8.2.9.6. Regional
Bifurcation
8.2.9.6.1. North
America
8.2.9.6.1.1. Market
Estimation, 2013 – 2018
8.2.9.6.1.2. Market
Forecast, 2019 – 2027
8.2.9.6.2. Europe
8.2.9.6.2.1. Market
Estimation, 2013 – 2018
8.2.9.6.2.2. Market
Forecast, 2019 – 2027
8.2.9.6.3. Asia
Pacific
8.2.9.6.3.1. Market
Estimation, 2013 – 2018
8.2.9.6.3.2. Market
Forecast, 2019 – 2027
8.2.9.6.4. Middle
East and Africa
8.2.9.6.4.1. Market
Estimation, 2013 – 2018
8.2.9.6.4.2. Market
Forecast, 2019 – 2027
8.2.9.6.5. Latin
America
8.2.9.6.5.1. Market
Estimation, 2013 – 2018
8.2.9.6.5.2. Market
Forecast, 2019 – 2027
8.2.10. Neurosteroids
8.2.10.1. Definition
8.2.10.2. Market
Penetration, 2018
8.2.10.3. Market
Estimation, 2013 – 2018
8.2.10.4. Market
Forecast, 2019 – 2027
8.2.10.5. Compound
Annual Growth Rate (CAGR)
8.2.10.6. Regional
Bifurcation
8.2.10.6.1. North
America
8.2.10.6.1.1. Market
Estimation, 2013 – 2018
8.2.10.6.1.2. Market
Forecast, 2019 – 2027
8.2.10.6.2. Europe
8.2.10.6.2.1. Market
Estimation, 2013 – 2018
8.2.10.6.2.2. Market
Forecast, 2019 – 2027
8.2.10.6.3. Asia
Pacific
8.2.10.6.3.1. Market
Estimation, 2013 – 2018
8.2.10.6.3.2. Market
Forecast, 2019 – 2027
8.2.10.6.4. Middle
East and Africa
8.2.10.6.4.1. Market
Estimation, 2013 – 2018
8.2.10.6.4.2. Market
Forecast, 2019 – 2027
8.2.10.6.5. Latin
America
8.2.10.6.5.1. Market
Estimation, 2013 – 2018
8.2.10.6.5.2. Market
Forecast, 2019 – 2027
8.2.11. Nutraceuticals
8.2.11.1. Definition
8.2.11.2. Market
Penetration, 2018
8.2.11.3. Market
Estimation, 2013 – 2018
8.2.11.4. Market
Forecast, 2019 – 2027
8.2.11.5. Compound
Annual Growth Rate (CAGR)
8.2.11.6. Regional
Bifurcation
8.2.11.6.1. North
America
8.2.11.6.1.1. Market
Estimation, 2013 – 2018
8.2.11.6.1.2. Market
Forecast, 2019 – 2027
8.2.11.6.2. Europe
8.2.11.6.2.1. Market
Estimation, 2013 – 2018
8.2.11.6.2.2. Market
Forecast, 2019 – 2027
8.2.11.6.3. Asia
Pacific
8.2.11.6.3.1. Market
Estimation, 2013 – 2018
8.2.11.6.3.2. Market
Forecast, 2019 – 2027
8.2.11.6.4. Middle
East and Africa
8.2.11.6.4.1. Market
Estimation, 2013 – 2018
8.2.11.6.4.2. Market
Forecast, 2019 – 2027
8.2.11.6.5. Latin
America
8.2.11.6.5.1. Market
Estimation, 2013 – 2018
8.2.11.6.5.2. Market
Forecast, 2019 – 2027
8.2.12. Pathway
Inhibitor
8.2.12.1. Definition
8.2.12.2. Market
Penetration, 2018
8.2.12.3. Market
Estimation, 2013 – 2018
8.2.12.4. Market
Forecast, 2019 – 2027
8.2.12.5. Compound
Annual Growth Rate (CAGR)
8.2.12.6. Regional
Bifurcation
8.2.12.6.1. North
America
8.2.12.6.1.1. Market
Estimation, 2013 – 2018
8.2.12.6.1.2. Market
Forecast, 2019 – 2027
8.2.12.6.2. Europe
8.2.12.6.2.1. Market
Estimation, 2013 – 2018
8.2.12.6.2.2. Market
Forecast, 2019 – 2027
8.2.12.6.3. Asia
Pacific
8.2.12.6.3.1. Market
Estimation, 2013 – 2018
8.2.12.6.3.2. Market
Forecast, 2019 – 2027
8.2.12.6.4. Middle
East and Africa
8.2.12.6.4.1. Market
Estimation, 2013 – 2018
8.2.12.6.4.2. Market
Forecast, 2019 – 2027
8.2.12.6.5. Latin
America
8.2.12.6.5.1. Market
Estimation, 2013 – 2018
8.2.12.6.5.2. Market
Forecast, 2019 – 2027
8.2.13. Others
(Vaccines, Toxins, etc.)
8.2.13.1. Definition
8.2.13.2. Market
Penetration, 2018
8.2.13.3. Market
Estimation, 2013 – 2018
8.2.13.4. Market
Forecast, 2019 – 2027
8.2.13.5. Compound
Annual Growth Rate (CAGR)
8.2.13.6. Regional
Bifurcation
8.2.13.6.1. North
America
8.2.13.6.1.1. Market
Estimation, 2013 – 2018
8.2.13.6.1.2. Market
Forecast, 2019 – 2027
8.2.13.6.2. Europe
8.2.13.6.2.1. Market
Estimation, 2013 – 2018
8.2.13.6.2.2. Market
Forecast, 2019 – 2027
8.2.13.6.3. Asia
Pacific
8.2.13.6.3.1. Market
Estimation, 2013 – 2018
8.2.13.6.3.2. Market
Forecast, 2019 – 2027
8.2.13.6.4. Middle
East and Africa
8.2.13.6.4.1. Market
Estimation, 2013 – 2018
8.2.13.6.4.2. Market
Forecast, 2019 – 2027
8.2.13.6.5. Latin
America
8.2.13.6.5.1. Market
Estimation, 2013 – 2018
8.2.13.6.5.2. Market
Forecast, 2019 – 2027
8.3. Key
Segment for Channeling Investments
8.3.1. By Drugs
Type
9. Global Neuroprotection Drugs Market Analysis and Forecasts,
2019 – 2027
9.1. Overview
9.2. Global
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application
9.2.1. Cerebrovascular
Disease (Definition, Market Penetration (2018), Market Estimation (2013 –
2018), Market Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR),
Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and
Africa, Latin America) and Information on ischemic stroke, hemorrhagic stroke,
cerebrovascular anomalies)
9.2.1.1. ischemic
stroke
9.2.1.2. hemorrhagic
stroke
9.2.1.3. cerebrovascular
anomalies
9.2.1.3.1. intracranial
aneurysms
9.2.1.3.2. arteriovenous
malformations
9.2.2. Neurodegenerative
Disorders (Definition, Market Penetration (2018), Market Estimation (2013 –
2018), Market Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR),
Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and
Africa, Latin America) and Information on Alzheimer’s Disease, Parkinson’s
Disease, Amyotrophic Lateral Sclerosis, Progressive supranuclear palsy (PSP),
Corticobasal Degeneration (CBD), Frontotemporal Dementia (FTD), Dementia With
Lewy Bodies (DLB), Huntington’s Disease (HD), Others (multiple system atrophy
(MSA), chronic traumatic encephalopathy (CTE), etc.))
9.2.2.1. Alzheimer’s
Disease
9.2.2.2. Parkinson’s
Disease
9.2.2.3. Amyotrophic
Lateral Sclerosis
9.2.2.4. Progressive
supranuclear palsy (PSP)
9.2.2.5. Corticobasal
Degeneration (CBD)
9.2.2.6. Frontotemporal
Dementia (FTD)
9.2.2.7. Dementia
With Lewy Bodies (DLB)
9.2.2.8. Huntington’s
Disease (HD)
9.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
9.2.3. Traumatic
CNS Injuries (Definition, Market Penetration (2018), Market Estimation (2013 –
2018), Market Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR),
Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and
Africa, Latin America) and Information on Coup-Contrecoup Brain Injury,
Concussion, Brain Contusion, Diffuse Axonal Injury, Penetrating Injury, Second
Impact Syndrome, Others)
9.2.3.1. Coup-Contrecoup
Brain Injury
9.2.3.2. Concussion
9.2.3.3. Brain
Contusion
9.2.3.4. Diffuse
Axonal Injury
9.2.3.5. Penetrating
Injury
9.2.3.6. Second
Impact Syndrome
9.2.3.7. Others
9.2.4. Others
9.2.4.1. Definition
9.2.4.2. Market
Penetration, 2018
9.2.4.3. Market
Estimation, 2013 – 2018
9.2.4.4. Market
Forecast, 2019 – 2027
9.2.4.5. Compound
Annual Growth Rate (CAGR)
9.2.4.6. Regional
Bifurcation
9.2.4.6.1. North
America
9.2.4.6.1.1. Market
Estimation, 2013 – 2018
9.2.4.6.1.2. Market
Forecast, 2019 – 2027
9.2.4.6.2. Europe
9.2.4.6.2.1. Market
Estimation, 2013 – 2018
9.2.4.6.2.2. Market
Forecast, 2019 – 2027
9.2.4.6.3. Asia
Pacific
9.2.4.6.3.1. Market
Estimation, 2013 – 2018
9.2.4.6.3.2. Market
Forecast, 2019 – 2027
9.2.4.6.4. Middle
East and Africa
9.2.4.6.4.1. Market
Estimation, 2013 – 2018
9.2.4.6.4.2. Market
Forecast, 2019 – 2027
9.2.4.6.5. Latin
America
9.2.4.6.5.1. Market
Estimation, 2013 – 2018
9.2.4.6.5.2. Market
Forecast, 2019 – 2027
9.3. Key
Segment for Channeling Investments
9.3.1. By Application
10. North America Neuroprotection Drugs Market Analysis and
Forecasts, 2019 - 2027
10.1. Overview
10.1.1. North
America Neuroprotection Drugs Market Revenue (US$ Mn)
10.2. North
America Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs
Type
10.2.1. Anesthetics
10.2.2. Antagonists
10.2.3. Antibiotics
10.2.4. Antidepressants
10.2.5. Antiepileptic
agents
10.2.6. Anti-inflammatory
agents
10.2.7. Antioxidants/free
radical scavengers
10.2.8. Cytokines
10.2.9. Ion
Channel Blockers
10.2.10. Neurosteroids
10.2.11. Nutraceuticals
10.2.12. Pathway
Inhibitor
10.2.13. Others
(Vaccines, Toxins, etc.)
10.3. North
America Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
10.3.1. Cerebrovascular
Disease
10.3.1.1. ischemic
stroke
10.3.1.2. hemorrhagic
stroke
10.3.1.3. cerebrovascular
anomalies
10.3.1.3.1. intracranial
aneurysms
10.3.1.3.2. arteriovenous
malformations
10.3.2. Neurodegenerative
Disorders
10.3.2.1. Alzheimer’s
Disease
10.3.2.2. Parkinson’s
Disease
10.3.2.3. Amyotrophic
Lateral Sclerosis
10.3.2.4. Progressive
supranuclear palsy (PSP)
10.3.2.5. Corticobasal
Degeneration (CBD)
10.3.2.6. Frontotemporal
Dementia (FTD)
10.3.2.7. Dementia
With Lewy Bodies (DLB)
10.3.2.8. Huntington’s
Disease (HD)
10.3.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
10.3.3. Traumatic
CNS Injuries
10.3.3.1. Coup-Contrecoup
Brain Injury
10.3.3.2. Concussion
10.3.3.3. Brain
Contusion
10.3.3.4. Diffuse
Axonal Injury
10.3.3.5. Penetrating
Injury
10.3.3.6. Second
Impact Syndrome
10.3.3.7. Others
10.3.4. Others
10.4. North
America Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Country
10.4.1. U.S
10.4.1.1. U.S
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type
10.4.1.1.1. Anesthetics
10.4.1.1.2. Antagonists
10.4.1.1.3. Antibiotics
10.4.1.1.4. Antidepressants
10.4.1.1.5. Antiepileptic
agents
10.4.1.1.6. Anti-inflammatory
agents
10.4.1.1.7. Antioxidants/free
radical scavengers
10.4.1.1.8. Cytokines
10.4.1.1.9. Ion
Channel Blockers
10.4.1.1.10. Neurosteroids
10.4.1.1.11. Nutraceuticals
10.4.1.1.12. Pathway
Inhibitor
10.4.1.1.13. Others
(Vaccines, Toxins, etc.)
10.4.1.2. U.S
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application
10.4.1.2.1. Cerebrovascular
Disease
10.4.1.2.1.1. ischemic
stroke
10.4.1.2.1.2. hemorrhagic
stroke
10.4.1.2.1.3. cerebrovascular
anomalies
10.4.1.2.1.3.1. intracranial aneurysms
10.4.1.2.1.3.2. arteriovenous malformations
10.4.1.2.2. Neurodegenerative
Disorders
10.4.1.2.2.1. Alzheimer’s
Disease
10.4.1.2.2.2. Parkinson’s
Disease
10.4.1.2.2.3. Amyotrophic
Lateral Sclerosis
10.4.1.2.2.4. Progressive
supranuclear palsy (PSP)
10.4.1.2.2.5. Corticobasal
Degeneration (CBD)
10.4.1.2.2.6. Frontotemporal
Dementia (FTD)
10.4.1.2.2.7. Dementia
With Lewy Bodies (DLB)
10.4.1.2.2.8. Huntington’s
Disease (HD)
10.4.1.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
10.4.1.2.3. Traumatic
CNS Injuries
10.4.1.2.3.1. Coup-Contrecoup
Brain Injury
10.4.1.2.3.2. Concussion
10.4.1.2.3.3. Brain
Contusion
10.4.1.2.3.4. Diffuse
Axonal Injury
10.4.1.2.3.5. Penetrating
Injury
10.4.1.2.3.6. Second
Impact Syndrome
10.4.1.2.3.7. Others
10.4.1.2.4. Others
10.4.2. Canada
10.4.2.1. Canada
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type
10.4.2.1.1. Anesthetics
10.4.2.1.2. Antagonists
10.4.2.1.3. Antibiotics
10.4.2.1.4. Antidepressants
10.4.2.1.5. Antiepileptic
agents
10.4.2.1.6. Anti-inflammatory
agents
10.4.2.1.7. Antioxidants/free
radical scavengers
10.4.2.1.8. Cytokines
10.4.2.1.9. Ion
Channel Blockers
10.4.2.1.10. Neurosteroids
10.4.2.1.11. Nutraceuticals
10.4.2.1.12. Pathway
Inhibitor
10.4.2.1.13. Others
(Vaccines, Toxins, etc.)
10.4.2.2. Canada
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application
10.4.2.2.1. Cerebrovascular
Disease
10.4.2.2.1.1. ischemic
stroke
10.4.2.2.1.2. hemorrhagic
stroke
10.4.2.2.1.3. cerebrovascular
anomalies
10.4.2.2.1.3.1. intracranial aneurysms
10.4.2.2.1.3.2. arteriovenous malformations
10.4.2.2.2. Neurodegenerative
Disorders
10.4.2.2.2.1. Alzheimer’s
Disease
10.4.2.2.2.2. Parkinson’s
Disease
10.4.2.2.2.3. Amyotrophic
Lateral Sclerosis
10.4.2.2.2.4. Progressive
supranuclear palsy (PSP)
10.4.2.2.2.5. Corticobasal
Degeneration (CBD)
10.4.2.2.2.6. Frontotemporal
Dementia (FTD)
10.4.2.2.2.7. Dementia
With Lewy Bodies (DLB)
10.4.2.2.2.8. Huntington’s
Disease (HD)
10.4.2.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
10.4.2.2.3. Traumatic
CNS Injuries
10.4.2.2.3.1. Coup-Contrecoup
Brain Injury
10.4.2.2.3.2. Concussion
10.4.2.2.3.3. Brain
Contusion
10.4.2.2.3.4. Diffuse
Axonal Injury
10.4.2.2.3.5. Penetrating
Injury
10.4.2.2.3.6. Second
Impact Syndrome
10.4.2.2.3.7. Others
10.4.2.2.4. Others
10.4.3. Mexico
10.4.3.1. Mexico
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type
10.4.3.1.1. Anesthetics
10.4.3.1.2. Antagonists
10.4.3.1.3. Antibiotics
10.4.3.1.4. Antidepressants
10.4.3.1.5. Antiepileptic
agents
10.4.3.1.6. Anti-inflammatory
agents
10.4.3.1.7. Antioxidants/free
radical scavengers
10.4.3.1.8. Cytokines
10.4.3.1.9. Ion
Channel Blockers
10.4.3.1.10. Neurosteroids
10.4.3.1.11. Nutraceuticals
10.4.3.1.12. Pathway
Inhibitor
10.4.3.1.13. Others
(Vaccines, Toxins, etc.)
10.4.3.2. Mexico
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application
10.4.3.2.1. Cerebrovascular
Disease
10.4.3.2.1.1. ischemic
stroke
10.4.3.2.1.2. hemorrhagic
stroke
10.4.3.2.1.3. cerebrovascular
anomalies
10.4.3.2.1.3.1. intracranial aneurysms
10.4.3.2.1.3.2. arteriovenous malformations
10.4.3.2.2. Neurodegenerative
Disorders
10.4.3.2.2.1. Alzheimer’s
Disease
10.4.3.2.2.2. Parkinson’s
Disease
10.4.3.2.2.3. Amyotrophic
Lateral Sclerosis
10.4.3.2.2.4. Progressive
supranuclear palsy (PSP)
10.4.3.2.2.5. Corticobasal
Degeneration (CBD)
10.4.3.2.2.6. Frontotemporal
Dementia (FTD)
10.4.3.2.2.7. Dementia
With Lewy Bodies (DLB)
10.4.3.2.2.8. Huntington’s
Disease (HD)
10.4.3.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
10.4.3.2.3. Traumatic
CNS Injuries
10.4.3.2.3.1. Coup-Contrecoup
Brain Injury
10.4.3.2.3.2. Concussion
10.4.3.2.3.3. Brain
Contusion
10.4.3.2.3.4. Diffuse
Axonal Injury
10.4.3.2.3.5. Penetrating
Injury
10.4.3.2.3.6. Second
Impact Syndrome
10.4.3.2.3.7. Others
10.4.3.2.4. Others
10.4.4. Rest of
North America
10.4.4.1. Rest
of North America Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts,
By Drugs Type
10.4.4.1.1. Anesthetics
10.4.4.1.2. Antagonists
10.4.4.1.3. Antibiotics
10.4.4.1.4. Antidepressants
10.4.4.1.5. Antiepileptic
agents
10.4.4.1.6. Anti-inflammatory
agents
10.4.4.1.7. Antioxidants/free
radical scavengers
10.4.4.1.8. Cytokines
10.4.4.1.9. Ion
Channel Blockers
10.4.4.1.10. Neurosteroids
10.4.4.1.11. Nutraceuticals
10.4.4.1.12. Pathway
Inhibitor
10.4.4.1.13. Others
(Vaccines, Toxins, etc.)
10.4.4.2. Rest of
North America Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
10.4.4.2.1. Cerebrovascular
Disease
10.4.4.2.1.1. ischemic
stroke
10.4.4.2.1.2. hemorrhagic
stroke
10.4.4.2.1.3. cerebrovascular
anomalies
10.4.4.2.1.3.1. intracranial aneurysms
10.4.4.2.1.3.2. arteriovenous malformations
10.4.4.2.2. Neurodegenerative
Disorders
10.4.4.2.2.1. Alzheimer’s
Disease
10.4.4.2.2.2. Parkinson’s
Disease
10.4.4.2.2.3. Amyotrophic
Lateral Sclerosis
10.4.4.2.2.4. Progressive
supranuclear palsy (PSP)
10.4.4.2.2.5. Corticobasal
Degeneration (CBD)
10.4.4.2.2.6. Frontotemporal
Dementia (FTD)
10.4.4.2.2.7. Dementia
With Lewy Bodies (DLB)
10.4.4.2.2.8. Huntington’s
Disease (HD)
10.4.4.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
10.4.4.2.3. Traumatic
CNS Injuries
10.4.4.2.3.1. Coup-Contrecoup
Brain Injury
10.4.4.2.3.2. Concussion
10.4.4.2.3.3. Brain
Contusion
10.4.4.2.3.4. Diffuse
Axonal Injury
10.4.4.2.3.5. Penetrating
Injury
10.4.4.2.3.6. Second
Impact Syndrome
10.4.4.2.3.7. Others
10.4.4.2.4. Others
10.5. Key
Segment for Channeling Investments
10.5.1. By
Country
10.5.2. By
Drugs Type
10.5.3. By
Application
11. Europe Neuroprotection Drugs Market Analysis and Forecasts,
2019 - 2027
11.1. Overview
11.1.1. Europe
Neuroprotection Drugs Market Revenue (US$ Mn)
11.2. Europe
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type
11.2.1. Anesthetics
11.2.2. Antagonists
11.2.3. Antibiotics
11.2.4. Antidepressants
11.2.5. Antiepileptic
agents
11.2.6. Anti-inflammatory
agents
11.2.7. Antioxidants/free
radical scavengers
11.2.8. Cytokines
11.2.9. Ion
Channel Blockers
11.2.10. Neurosteroids
11.2.11. Nutraceuticals
11.2.12. Pathway
Inhibitor
11.2.13. Others
(Vaccines, Toxins, etc.)
11.3. Europe
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application
11.3.1. Cerebrovascular
Disease
11.3.1.1. ischemic
stroke
11.3.1.2. hemorrhagic
stroke
11.3.1.3. cerebrovascular
anomalies
11.3.1.3.1. intracranial
aneurysms
11.3.1.3.2. arteriovenous
malformations
11.3.2. Neurodegenerative
Disorders
11.3.2.1. Alzheimer’s
Disease
11.3.2.2. Parkinson’s
Disease
11.3.2.3. Amyotrophic
Lateral Sclerosis
11.3.2.4. Progressive
supranuclear palsy (PSP)
11.3.2.5. Corticobasal
Degeneration (CBD)
11.3.2.6. Frontotemporal
Dementia (FTD)
11.3.2.7. Dementia
With Lewy Bodies (DLB)
11.3.2.8. Huntington’s
Disease (HD)
11.3.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
11.3.3. Traumatic
CNS Injuries
11.3.3.1. Coup-Contrecoup
Brain Injury
11.3.3.2. Concussion
11.3.3.3. Brain
Contusion
11.3.3.4. Diffuse
Axonal Injury
11.3.3.5. Penetrating
Injury
11.3.3.6. Second
Impact Syndrome
11.3.3.7. Others
11.3.4. Others
11.4. Europe
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Country
11.4.1. France
11.4.1.1. France
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type
11.4.1.1.1. Anesthetics
11.4.1.1.2. Antagonists
11.4.1.1.3. Antibiotics
11.4.1.1.4. Antidepressants
11.4.1.1.5. Antiepileptic
agents
11.4.1.1.6. Anti-inflammatory
agents
11.4.1.1.7. Antioxidants/free
radical scavengers
11.4.1.1.8. Cytokines
11.4.1.1.9. Ion
Channel Blockers
11.4.1.1.10. Neurosteroids
11.4.1.1.11. Nutraceuticals
11.4.1.1.12. Pathway
Inhibitor
11.4.1.1.13. Others
(Vaccines, Toxins, etc.)
11.4.1.2. France
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application
11.4.1.2.1. Cerebrovascular
Disease
11.4.1.2.1.1. ischemic
stroke
11.4.1.2.1.2. hemorrhagic
stroke
11.4.1.2.1.3. cerebrovascular
anomalies
11.4.1.2.1.3.1. intracranial aneurysms
11.4.1.2.1.3.2. arteriovenous malformations
11.4.1.2.2. Neurodegenerative
Disorders
11.4.1.2.2.1. Alzheimer’s
Disease
11.4.1.2.2.2. Parkinson’s
Disease
11.4.1.2.2.3. Amyotrophic
Lateral Sclerosis
11.4.1.2.2.4. Progressive
supranuclear palsy (PSP)
11.4.1.2.2.5. Corticobasal
Degeneration (CBD)
11.4.1.2.2.6. Frontotemporal
Dementia (FTD)
11.4.1.2.2.7. Dementia
With Lewy Bodies (DLB)
11.4.1.2.2.8. Huntington’s
Disease (HD)
11.4.1.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
11.4.1.2.3. Traumatic
CNS Injuries
11.4.1.2.3.1. Coup-Contrecoup
Brain Injury
11.4.1.2.3.2. Concussion
11.4.1.2.3.3. Brain
Contusion
11.4.1.2.3.4. Diffuse
Axonal Injury
11.4.1.2.3.5. Penetrating
Injury
11.4.1.2.3.6. Second
Impact Syndrome
11.4.1.2.3.7. Others
11.4.1.2.4. Others
11.4.2. The UK
11.4.2.1. The
UK Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type
11.4.2.1.1. Anesthetics
11.4.2.1.2. Antagonists
11.4.2.1.3. Antibiotics
11.4.2.1.4. Antidepressants
11.4.2.1.5. Antiepileptic
agents
11.4.2.1.6. Anti-inflammatory
agents
11.4.2.1.7. Antioxidants/free
radical scavengers
11.4.2.1.8. Cytokines
11.4.2.1.9. Ion
Channel Blockers
11.4.2.1.10. Neurosteroids
11.4.2.1.11. Nutraceuticals
11.4.2.1.12. Pathway
Inhibitor
11.4.2.1.13. Others
(Vaccines, Toxins, etc.)
11.4.2.2. The
UK Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application
11.4.2.2.1. Cerebrovascular
Disease
11.4.2.2.1.1. ischemic
stroke
11.4.2.2.1.2. hemorrhagic
stroke
11.4.2.2.1.3. cerebrovascular
anomalies
11.4.2.2.1.3.1. intracranial aneurysms
11.4.2.2.1.3.2. arteriovenous malformations
11.4.2.2.2. Neurodegenerative
Disorders
11.4.2.2.2.1. Alzheimer’s
Disease
11.4.2.2.2.2. Parkinson’s
Disease
11.4.2.2.2.3. Amyotrophic
Lateral Sclerosis
11.4.2.2.2.4. Progressive
supranuclear palsy (PSP)
11.4.2.2.2.5. Corticobasal
Degeneration (CBD)
11.4.2.2.2.6. Frontotemporal
Dementia (FTD)
11.4.2.2.2.7. Dementia
With Lewy Bodies (DLB)
11.4.2.2.2.8. Huntington’s
Disease (HD)
11.4.2.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
11.4.2.2.3. Traumatic
CNS Injuries
11.4.2.2.3.1. Coup-Contrecoup
Brain Injury
11.4.2.2.3.2. Concussion
11.4.2.2.3.3. Brain
Contusion
11.4.2.2.3.4. Diffuse
Axonal Injury
11.4.2.2.3.5. Penetrating
Injury
11.4.2.2.3.6. Second
Impact Syndrome
11.4.2.2.3.7. Others
11.4.2.2.4. Others
11.4.3. Spain
11.4.3.1. Spain
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type
11.4.3.1.1. Anesthetics
11.4.3.1.2. Antagonists
11.4.3.1.3. Antibiotics
11.4.3.1.4. Antidepressants
11.4.3.1.5. Antiepileptic
agents
11.4.3.1.6. Anti-inflammatory
agents
11.4.3.1.7. Antioxidants/free
radical scavengers
11.4.3.1.8. Cytokines
11.4.3.1.9. Ion
Channel Blockers
11.4.3.1.10. Neurosteroids
11.4.3.1.11. Nutraceuticals
11.4.3.1.12. Pathway
Inhibitor
11.4.3.1.13. Others
(Vaccines, Toxins, etc.)
11.4.3.2. Spain
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application
11.4.3.2.1. Cerebrovascular
Disease
11.4.3.2.1.1. ischemic
stroke
11.4.3.2.1.2. hemorrhagic
stroke
11.4.3.2.1.3. cerebrovascular
anomalies
11.4.3.2.1.3.1. intracranial aneurysms
11.4.3.2.1.3.2. arteriovenous malformations
11.4.3.2.2. Neurodegenerative
Disorders
11.4.3.2.2.1. Alzheimer’s
Disease
11.4.3.2.2.2. Parkinson’s
Disease
11.4.3.2.2.3. Amyotrophic
Lateral Sclerosis
11.4.3.2.2.4. Progressive
supranuclear palsy (PSP)
11.4.3.2.2.5. Corticobasal
Degeneration (CBD)
11.4.3.2.2.6. Frontotemporal
Dementia (FTD)
11.4.3.2.2.7. Dementia
With Lewy Bodies (DLB)
11.4.3.2.2.8. Huntington’s
Disease (HD)
11.4.3.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
11.4.3.2.3. Traumatic
CNS Injuries
11.4.3.2.3.1. Coup-Contrecoup
Brain Injury
11.4.3.2.3.2. Concussion
11.4.3.2.3.3. Brain
Contusion
11.4.3.2.3.4. Diffuse
Axonal Injury
11.4.3.2.3.5. Penetrating
Injury
11.4.3.2.3.6. Second
Impact Syndrome
11.4.3.2.3.7. Others
11.4.3.2.4. Others
11.4.4. Germany
11.4.4.1. Germany
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type
11.4.4.1.1. Anesthetics
11.4.4.1.2. Antagonists
11.4.4.1.3. Antibiotics
11.4.4.1.4. Antidepressants
11.4.4.1.5. Antiepileptic
agents
11.4.4.1.6. Anti-inflammatory
agents
11.4.4.1.7. Antioxidants/free
radical scavengers
11.4.4.1.8. Cytokines
11.4.4.1.9. Ion
Channel Blockers
11.4.4.1.10. Neurosteroids
11.4.4.1.11. Nutraceuticals
11.4.4.1.12. Pathway
Inhibitor
11.4.4.1.13. Others
(Vaccines, Toxins, etc.)
11.4.4.2. Germany
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application
11.4.4.2.1. Cerebrovascular
Disease
11.4.4.2.1.1. ischemic
stroke
11.4.4.2.1.2. hemorrhagic
stroke
11.4.4.2.1.3. cerebrovascular
anomalies
11.4.4.2.1.3.1. intracranial aneurysms
11.4.4.2.1.3.2. arteriovenous malformations
11.4.4.2.2. Neurodegenerative
Disorders
11.4.4.2.2.1. Alzheimer’s
Disease
11.4.4.2.2.2. Parkinson’s
Disease
11.4.4.2.2.3. Amyotrophic
Lateral Sclerosis
11.4.4.2.2.4. Progressive
supranuclear palsy (PSP)
11.4.4.2.2.5. Corticobasal
Degeneration (CBD)
11.4.4.2.2.6. Frontotemporal
Dementia (FTD)
11.4.4.2.2.7. Dementia
With Lewy Bodies (DLB)
11.4.4.2.2.8. Huntington’s
Disease (HD)
11.4.4.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
11.4.4.2.3. Traumatic
CNS Injuries
11.4.4.2.3.1. Coup-Contrecoup
Brain Injury
11.4.4.2.3.2. Concussion
11.4.4.2.3.3. Brain
Contusion
11.4.4.2.3.4. Diffuse
Axonal Injury
11.4.4.2.3.5. Penetrating
Injury
11.4.4.2.3.6. Second
Impact Syndrome
11.4.4.2.3.7. Others
11.4.4.2.4. Others
11.4.5. Italy
11.4.5.1. Italy
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type
11.4.5.1.1. Anesthetics
11.4.5.1.2. Antagonists
11.4.5.1.3. Antibiotics
11.4.5.1.4. Antidepressants
11.4.5.1.5. Antiepileptic
agents
11.4.5.1.6. Anti-inflammatory
agents
11.4.5.1.7. Antioxidants/free
radical scavengers
11.4.5.1.8. Cytokines
11.4.5.1.9. Ion
Channel Blockers
11.4.5.1.10. Neurosteroids
11.4.5.1.11. Nutraceuticals
11.4.5.1.12. Pathway
Inhibitor
11.4.5.1.13. Others
(Vaccines, Toxins, etc.)
11.4.5.2. Italy
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application
11.4.5.2.1. Cerebrovascular
Disease
11.4.5.2.1.1. ischemic
stroke
11.4.5.2.1.2. hemorrhagic
stroke
11.4.5.2.1.3. cerebrovascular
anomalies
11.4.5.2.1.3.1. intracranial aneurysms
11.4.5.2.1.3.2. arteriovenous malformations
11.4.5.2.2. Neurodegenerative
Disorders
11.4.5.2.2.1. Alzheimer’s
Disease
11.4.5.2.2.2. Parkinson’s
Disease
11.4.5.2.2.3. Amyotrophic
Lateral Sclerosis
11.4.5.2.2.4. Progressive
supranuclear palsy (PSP)
11.4.5.2.2.5. Corticobasal
Degeneration (CBD)
11.4.5.2.2.6. Frontotemporal
Dementia (FTD)
11.4.5.2.2.7. Dementia
With Lewy Bodies (DLB)
11.4.5.2.2.8. Huntington’s
Disease (HD)
11.4.5.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
11.4.5.2.3. Traumatic
CNS Injuries
11.4.5.2.3.1. Coup-Contrecoup
Brain Injury
11.4.5.2.3.2. Concussion
11.4.5.2.3.3. Brain
Contusion
11.4.5.2.3.4. Diffuse
Axonal Injury
11.4.5.2.3.5. Penetrating
Injury
11.4.5.2.3.6. Second
Impact Syndrome
11.4.5.2.3.7. Others
11.4.5.2.4. Others
11.4.6. Nordic
Countries
11.4.6.1. Nordic
Countries Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs
Type
11.4.6.1.1. Anesthetics
11.4.6.1.2. Antagonists
11.4.6.1.3. Antibiotics
11.4.6.1.4. Antidepressants
11.4.6.1.5. Antiepileptic
agents
11.4.6.1.6. Anti-inflammatory
agents
11.4.6.1.7. Antioxidants/free
radical scavengers
11.4.6.1.8. Cytokines
11.4.6.1.9. Ion
Channel Blockers
11.4.6.1.10. Neurosteroids
11.4.6.1.11. Nutraceuticals
11.4.6.1.12. Pathway
Inhibitor
11.4.6.1.13. Others
(Vaccines, Toxins, etc.)
11.4.6.2. Nordic
Countries Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
11.4.6.2.1. Cerebrovascular
Disease
11.4.6.2.1.1. ischemic
stroke
11.4.6.2.1.2. hemorrhagic
stroke
11.4.6.2.1.3. cerebrovascular
anomalies
11.4.6.2.1.3.1. intracranial aneurysms
11.4.6.2.1.3.2. arteriovenous malformations
11.4.6.2.2. Neurodegenerative
Disorders
11.4.6.2.2.1. Alzheimer’s
Disease
11.4.6.2.2.2. Parkinson’s
Disease
11.4.6.2.2.3. Amyotrophic
Lateral Sclerosis
11.4.6.2.2.4. Progressive
supranuclear palsy (PSP)
11.4.6.2.2.5. Corticobasal
Degeneration (CBD)
11.4.6.2.2.6. Frontotemporal
Dementia (FTD)
11.4.6.2.2.7. Dementia
With Lewy Bodies (DLB)
11.4.6.2.2.8. Huntington’s
Disease (HD)
11.4.6.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
11.4.6.2.3. Traumatic
CNS Injuries
11.4.6.2.3.1. Coup-Contrecoup
Brain Injury
11.4.6.2.3.2. Concussion
11.4.6.2.3.3. Brain
Contusion
11.4.6.2.3.4. Diffuse
Axonal Injury
11.4.6.2.3.5. Penetrating
Injury
11.4.6.2.3.6. Second
Impact Syndrome
11.4.6.2.3.7. Others
11.4.6.2.4. Others
11.4.6.3. Nordic
Countries Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By
Country
11.4.6.3.1. Denmark
11.4.6.3.2. Finland
11.4.6.3.3. Iceland
11.4.6.3.4. Sweden
11.4.6.3.5. Norway
11.4.7. Benelux
Union
11.4.7.1. Benelux
Union Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs
Type
11.4.7.1.1. Anesthetics
11.4.7.1.2. Antagonists
11.4.7.1.3. Antibiotics
11.4.7.1.4. Antidepressants
11.4.7.1.5. Antiepileptic
agents
11.4.7.1.6. Anti-inflammatory
agents
11.4.7.1.7. Antioxidants/free
radical scavengers
11.4.7.1.8. Cytokines
11.4.7.1.9. Ion
Channel Blockers
11.4.7.1.10. Neurosteroids
11.4.7.1.11. Nutraceuticals
11.4.7.1.12. Pathway
Inhibitor
11.4.7.1.13. Others
(Vaccines, Toxins, etc.)
11.4.7.2. Benelux
Union Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
11.4.7.2.1. Cerebrovascular
Disease
11.4.7.2.1.1. ischemic
stroke
11.4.7.2.1.2. hemorrhagic
stroke
11.4.7.2.1.3. cerebrovascular
anomalies
11.4.7.2.1.3.1. intracranial aneurysms
11.4.7.2.1.3.2. arteriovenous malformations
11.4.7.2.2. Neurodegenerative
Disorders
11.4.7.2.2.1. Alzheimer’s
Disease
11.4.7.2.2.2. Parkinson’s
Disease
11.4.7.2.2.3. Amyotrophic
Lateral Sclerosis
11.4.7.2.2.4. Progressive
supranuclear palsy (PSP)
11.4.7.2.2.5. Corticobasal
Degeneration (CBD)
11.4.7.2.2.6. Frontotemporal
Dementia (FTD)
11.4.7.2.2.7. Dementia
With Lewy Bodies (DLB)
11.4.7.2.2.8. Huntington’s
Disease (HD)
11.4.7.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
11.4.7.2.3. Traumatic
CNS Injuries
11.4.7.2.3.1. Coup-Contrecoup
Brain Injury
11.4.7.2.3.2. Concussion
11.4.7.2.3.3. Brain
Contusion
11.4.7.2.3.4. Diffuse
Axonal Injury
11.4.7.2.3.5. Penetrating
Injury
11.4.7.2.3.6. Second
Impact Syndrome
11.4.7.2.3.7. Others
11.4.7.2.4. Others
11.4.7.3. Benelux
Union Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Country
11.4.7.3.1. Belgium
11.4.7.3.2. The
Netherlands
11.4.7.3.3. Luxembourg
11.4.8. Rest of
Europe
11.4.8.1. Rest
of Europe Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs
Type
11.4.8.1.1. Anesthetics
11.4.8.1.2. Antagonists
11.4.8.1.3. Antibiotics
11.4.8.1.4. Antidepressants
11.4.8.1.5. Antiepileptic
agents
11.4.8.1.6. Anti-inflammatory
agents
11.4.8.1.7. Antioxidants/free
radical scavengers
11.4.8.1.8. Cytokines
11.4.8.1.9. Ion
Channel Blockers
11.4.8.1.10. Neurosteroids
11.4.8.1.11. Nutraceuticals
11.4.8.1.12. Pathway
Inhibitor
11.4.8.1.13. Others
(Vaccines, Toxins, etc.)
11.4.8.2. Rest
of Europe Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
11.4.8.2.1. Cerebrovascular
Disease
11.4.8.2.1.1. ischemic
stroke
11.4.8.2.1.2. hemorrhagic
stroke
11.4.8.2.1.3. cerebrovascular
anomalies
11.4.8.2.1.3.1. intracranial aneurysms
11.4.8.2.1.3.2. arteriovenous malformations
11.4.8.2.2. Neurodegenerative
Disorders
11.4.8.2.2.1. Alzheimer’s
Disease
11.4.8.2.2.2. Parkinson’s
Disease
11.4.8.2.2.3. Amyotrophic
Lateral Sclerosis
11.4.8.2.2.4. Progressive
supranuclear palsy (PSP)
11.4.8.2.2.5. Corticobasal
Degeneration (CBD)
11.4.8.2.2.6. Frontotemporal
Dementia (FTD)
11.4.8.2.2.7. Dementia
With Lewy Bodies (DLB)
11.4.8.2.2.8. Huntington’s
Disease (HD)
11.4.8.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
11.4.8.2.3. Traumatic
CNS Injuries
11.4.8.2.3.1. Coup-Contrecoup
Brain Injury
11.4.8.2.3.2. Concussion
11.4.8.2.3.3. Brain
Contusion
11.4.8.2.3.4. Diffuse
Axonal Injury
11.4.8.2.3.5. Penetrating
Injury
11.4.8.2.3.6. Second
Impact Syndrome
11.4.8.2.3.7. Others
11.4.8.2.4. Others
11.5. Key
Segment for Channeling Investments
11.5.1. By
Country
11.5.2. By
Drugs Type
11.5.3. By
Application
12. Asia Pacific Neuroprotection Drugs Market Analysis and
Forecasts, 2019 - 2027
12.1. Overview
12.1.1. Asia
Pacific Neuroprotection Drugs Market Revenue (US$ Mn)
12.2. Asia
Pacific Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs
Type
12.2.1. Anesthetics
12.2.2. Antagonists
12.2.3. Antibiotics
12.2.4. Antidepressants
12.2.5. Antiepileptic
agents
12.2.6. Anti-inflammatory
agents
12.2.7. Antioxidants/free
radical scavengers
12.2.8. Cytokines
12.2.9. Ion
Channel Blockers
12.2.10. Neurosteroids
12.2.11. Nutraceuticals
12.2.12. Pathway
Inhibitor
12.2.13. Others
(Vaccines, Toxins, etc.)
12.3. Asia
Pacific Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
12.3.1. Cerebrovascular
Disease
12.3.1.1. ischemic
stroke
12.3.1.2. hemorrhagic
stroke
12.3.1.3. cerebrovascular
anomalies
12.3.1.3.1. intracranial
aneurysms
12.3.1.3.2. arteriovenous
malformations
12.3.2. Neurodegenerative
Disorders
12.3.2.1. Alzheimer’s
Disease
12.3.2.2. Parkinson’s
Disease
12.3.2.3. Amyotrophic
Lateral Sclerosis
12.3.2.4. Progressive
supranuclear palsy (PSP)
12.3.2.5. Corticobasal
Degeneration (CBD)
12.3.2.6. Frontotemporal
Dementia (FTD)
12.3.2.7. Dementia
With Lewy Bodies (DLB)
12.3.2.8. Huntington’s
Disease (HD)
12.3.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
12.3.3. Traumatic
CNS Injuries
12.3.3.1. Coup-Contrecoup
Brain Injury
12.3.3.2. Concussion
12.3.3.3. Brain
Contusion
12.3.3.4. Diffuse
Axonal Injury
12.3.3.5. Penetrating
Injury
12.3.3.6. Second
Impact Syndrome
12.3.3.7. Others
12.3.4. Others
12.4. Asia
Pacific Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Country
12.4.1. China
12.4.1.1. China
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type
12.4.1.1.1. Anesthetics
12.4.1.1.2. Antagonists
12.4.1.1.3. Antibiotics
12.4.1.1.4. Antidepressants
12.4.1.1.5. Antiepileptic
agents
12.4.1.1.6. Anti-inflammatory
agents
12.4.1.1.7. Antioxidants/free
radical scavengers
12.4.1.1.8. Cytokines
12.4.1.1.9. Ion
Channel Blockers
12.4.1.1.10. Neurosteroids
12.4.1.1.11. Nutraceuticals
12.4.1.1.12. Pathway
Inhibitor
12.4.1.1.13. Others
(Vaccines, Toxins, etc.)
12.4.1.2. China
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application
12.4.1.2.1. Cerebrovascular
Disease
12.4.1.2.1.1. ischemic
stroke
12.4.1.2.1.2. hemorrhagic
stroke
12.4.1.2.1.3. cerebrovascular
anomalies
12.4.1.2.1.3.1. intracranial aneurysms
12.4.1.2.1.3.2. arteriovenous malformations
12.4.1.2.2. Neurodegenerative
Disorders
12.4.1.2.2.1. Alzheimer’s
Disease
12.4.1.2.2.2. Parkinson’s
Disease
12.4.1.2.2.3. Amyotrophic
Lateral Sclerosis
12.4.1.2.2.4. Progressive
supranuclear palsy (PSP)
12.4.1.2.2.5. Corticobasal
Degeneration (CBD)
12.4.1.2.2.6. Frontotemporal
Dementia (FTD)
12.4.1.2.2.7. Dementia
With Lewy Bodies (DLB)
12.4.1.2.2.8. Huntington’s
Disease (HD)
12.4.1.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
12.4.1.2.3. Traumatic
CNS Injuries
12.4.1.2.3.1. Coup-Contrecoup
Brain Injury
12.4.1.2.3.2. Concussion
12.4.1.2.3.3. Brain
Contusion
12.4.1.2.3.4. Diffuse
Axonal Injury
12.4.1.2.3.5. Penetrating
Injury
12.4.1.2.3.6. Second
Impact Syndrome
12.4.1.2.3.7. Others
12.4.1.2.4. Others
12.4.2. Japan
12.4.2.1. Japan
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type
12.4.2.1.1. Anesthetics
12.4.2.1.2. Antagonists
12.4.2.1.3. Antibiotics
12.4.2.1.4. Antidepressants
12.4.2.1.5. Antiepileptic
agents
12.4.2.1.6. Anti-inflammatory
agents
12.4.2.1.7. Antioxidants/free
radical scavengers
12.4.2.1.8. Cytokines
12.4.2.1.9. Ion
Channel Blockers
12.4.2.1.10. Neurosteroids
12.4.2.1.11. Nutraceuticals
12.4.2.1.12. Pathway
Inhibitor
12.4.2.1.13. Others
(Vaccines, Toxins, etc.)
12.4.2.2. Japan
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application
12.4.2.2.1. Cerebrovascular
Disease
12.4.2.2.1.1. ischemic
stroke
12.4.2.2.1.2. hemorrhagic
stroke
12.4.2.2.1.3. cerebrovascular
anomalies
12.4.2.2.1.3.1. intracranial aneurysms
12.4.2.2.1.3.2. arteriovenous malformations
12.4.2.2.2. Neurodegenerative
Disorders
12.4.2.2.2.1. Alzheimer’s
Disease
12.4.2.2.2.2. Parkinson’s
Disease
12.4.2.2.2.3. Amyotrophic
Lateral Sclerosis
12.4.2.2.2.4. Progressive
supranuclear palsy (PSP)
12.4.2.2.2.5. Corticobasal
Degeneration (CBD)
12.4.2.2.2.6. Frontotemporal
Dementia (FTD)
12.4.2.2.2.7. Dementia
With Lewy Bodies (DLB)
12.4.2.2.2.8. Huntington’s
Disease (HD)
12.4.2.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
12.4.2.2.3. Traumatic
CNS Injuries
12.4.2.2.3.1. Coup-Contrecoup
Brain Injury
12.4.2.2.3.2. Concussion
12.4.2.2.3.3. Brain
Contusion
12.4.2.2.3.4. Diffuse
Axonal Injury
12.4.2.2.3.5. Penetrating
Injury
12.4.2.2.3.6. Second
Impact Syndrome
12.4.2.2.3.7. Others
12.4.2.2.4. Others
12.4.3. India
12.4.3.1. India
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type
12.4.3.1.1. Anesthetics
12.4.3.1.2. Antagonists
12.4.3.1.3. Antibiotics
12.4.3.1.4. Antidepressants
12.4.3.1.5. Antiepileptic
agents
12.4.3.1.6. Anti-inflammatory
agents
12.4.3.1.7. Antioxidants/free
radical scavengers
12.4.3.1.8. Cytokines
12.4.3.1.9. Ion
Channel Blockers
12.4.3.1.10. Neurosteroids
12.4.3.1.11. Nutraceuticals
12.4.3.1.12. Pathway
Inhibitor
12.4.3.1.13. Others
(Vaccines, Toxins, etc.)
12.4.3.2. India
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application
12.4.3.2.1. Cerebrovascular
Disease
12.4.3.2.1.1. ischemic
stroke
12.4.3.2.1.2. hemorrhagic
stroke
12.4.3.2.1.3. cerebrovascular
anomalies
12.4.3.2.1.3.1. intracranial aneurysms
12.4.3.2.1.3.2. arteriovenous malformations
12.4.3.2.2. Neurodegenerative
Disorders
12.4.3.2.2.1. Alzheimer’s
Disease
12.4.3.2.2.2. Parkinson’s
Disease
12.4.3.2.2.3. Amyotrophic
Lateral Sclerosis
12.4.3.2.2.4. Progressive
supranuclear palsy (PSP)
12.4.3.2.2.5. Corticobasal
Degeneration (CBD)
12.4.3.2.2.6. Frontotemporal
Dementia (FTD)
12.4.3.2.2.7. Dementia
With Lewy Bodies (DLB)
12.4.3.2.2.8. Huntington’s
Disease (HD)
12.4.3.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
12.4.3.2.3. Traumatic
CNS Injuries
12.4.3.2.3.1. Coup-Contrecoup
Brain Injury
12.4.3.2.3.2. Concussion
12.4.3.2.3.3. Brain
Contusion
12.4.3.2.3.4. Diffuse
Axonal Injury
12.4.3.2.3.5. Penetrating
Injury
12.4.3.2.3.6. Second
Impact Syndrome
12.4.3.2.3.7. Others
12.4.3.2.4. Others
12.4.4. New
Zealand
12.4.4.1. New
Zealand Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs
Type
12.4.4.1.1. Anesthetics
12.4.4.1.2. Antagonists
12.4.4.1.3. Antibiotics
12.4.4.1.4. Antidepressants
12.4.4.1.5. Antiepileptic
agents
12.4.4.1.6. Anti-inflammatory
agents
12.4.4.1.7. Antioxidants/free
radical scavengers
12.4.4.1.8. Cytokines
12.4.4.1.9. Ion
Channel Blockers
12.4.4.1.10. Neurosteroids
12.4.4.1.11. Nutraceuticals
12.4.4.1.12. Pathway
Inhibitor
12.4.4.1.13. Others
(Vaccines, Toxins, etc.)
12.4.4.2. New
Zealand Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application
12.4.4.2.1. Cerebrovascular
Disease
12.4.4.2.1.1. ischemic
stroke
12.4.4.2.1.2. hemorrhagic
stroke
12.4.4.2.1.3. cerebrovascular
anomalies
12.4.4.2.1.3.1. intracranial aneurysms
12.4.4.2.1.3.2. arteriovenous malformations
12.4.4.2.2. Neurodegenerative
Disorders
12.4.4.2.2.1. Alzheimer’s
Disease
12.4.4.2.2.2. Parkinson’s
Disease
12.4.4.2.2.3. Amyotrophic
Lateral Sclerosis
12.4.4.2.2.4. Progressive
supranuclear palsy (PSP)
12.4.4.2.2.5. Corticobasal
Degeneration (CBD)
12.4.4.2.2.6. Frontotemporal
Dementia (FTD)
12.4.4.2.2.7. Dementia
With Lewy Bodies (DLB)
12.4.4.2.2.8. Huntington’s
Disease (HD)
12.4.4.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
12.4.4.2.3. Traumatic
CNS Injuries
12.4.4.2.3.1. Coup-Contrecoup
Brain Injury
12.4.4.2.3.2. Concussion
12.4.4.2.3.3. Brain
Contusion
12.4.4.2.3.4. Diffuse
Axonal Injury
12.4.4.2.3.5. Penetrating
Injury
12.4.4.2.3.6. Second
Impact Syndrome
12.4.4.2.3.7. Others
12.4.4.2.4. Others
12.4.5. Australia
12.4.5.1. Australia
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type
12.4.5.1.1. Anesthetics
12.4.5.1.2. Antagonists
12.4.5.1.3. Antibiotics
12.4.5.1.4. Antidepressants
12.4.5.1.5. Antiepileptic
agents
12.4.5.1.6. Anti-inflammatory
agents
12.4.5.1.7. Antioxidants/free
radical scavengers
12.4.5.1.8. Cytokines
12.4.5.1.9. Ion
Channel Blockers
12.4.5.1.10. Neurosteroids
12.4.5.1.11. Nutraceuticals
12.4.5.1.12. Pathway
Inhibitor
12.4.5.1.13. Others
(Vaccines, Toxins, etc.)
12.4.5.2. Australia
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application
12.4.5.2.1. Cerebrovascular
Disease
12.4.5.2.1.1. ischemic
stroke
12.4.5.2.1.2. hemorrhagic
stroke
12.4.5.2.1.3. cerebrovascular
anomalies
12.4.5.2.1.3.1. intracranial aneurysms
12.4.5.2.1.3.2. arteriovenous malformations
12.4.5.2.2. Neurodegenerative
Disorders
12.4.5.2.2.1. Alzheimer’s
Disease
12.4.5.2.2.2. Parkinson’s
Disease
12.4.5.2.2.3. Amyotrophic
Lateral Sclerosis
12.4.5.2.2.4. Progressive
supranuclear palsy (PSP)
12.4.5.2.2.5. Corticobasal
Degeneration (CBD)
12.4.5.2.2.6. Frontotemporal
Dementia (FTD)
12.4.5.2.2.7. Dementia
With Lewy Bodies (DLB)
12.4.5.2.2.8. Huntington’s
Disease (HD)
12.4.5.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
12.4.5.2.3. Traumatic
CNS Injuries
12.4.5.2.3.1. Coup-Contrecoup
Brain Injury
12.4.5.2.3.2. Concussion
12.4.5.2.3.3. Brain
Contusion
12.4.5.2.3.4. Diffuse
Axonal Injury
12.4.5.2.3.5. Penetrating
Injury
12.4.5.2.3.6. Second
Impact Syndrome
12.4.5.2.3.7. Others
12.4.5.2.4. Others
12.4.6. South
Korea
12.4.6.1. South
Korea Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs
Type
12.4.6.1.1. Anesthetics
12.4.6.1.2. Antagonists
12.4.6.1.3. Antibiotics
12.4.6.1.4. Antidepressants
12.4.6.1.5. Antiepileptic
agents
12.4.6.1.6. Anti-inflammatory
agents
12.4.6.1.7. Antioxidants/free
radical scavengers
12.4.6.1.8. Cytokines
12.4.6.1.9. Ion
Channel Blockers
12.4.6.1.10. Neurosteroids
12.4.6.1.11. Nutraceuticals
12.4.6.1.12. Pathway
Inhibitor
12.4.6.1.13. Others
(Vaccines, Toxins, etc.)
12.4.6.2. South
Korea Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
12.4.6.2.1. Cerebrovascular
Disease
12.4.6.2.1.1. ischemic
stroke
12.4.6.2.1.2. hemorrhagic
stroke
12.4.6.2.1.3. cerebrovascular
anomalies
12.4.6.2.1.3.1. intracranial aneurysms
12.4.6.2.1.3.2. arteriovenous malformations
12.4.6.2.2. Neurodegenerative
Disorders
12.4.6.2.2.1. Alzheimer’s
Disease
12.4.6.2.2.2. Parkinson’s
Disease
12.4.6.2.2.3. Amyotrophic
Lateral Sclerosis
12.4.6.2.2.4. Progressive
supranuclear palsy (PSP)
12.4.6.2.2.5. Corticobasal
Degeneration (CBD)
12.4.6.2.2.6. Frontotemporal
Dementia (FTD)
12.4.6.2.2.7. Dementia
With Lewy Bodies (DLB)
12.4.6.2.2.8. Huntington’s
Disease (HD)
12.4.6.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
12.4.6.2.3. Traumatic
CNS Injuries
12.4.6.2.3.1. Coup-Contrecoup
Brain Injury
12.4.6.2.3.2. Concussion
12.4.6.2.3.3. Brain
Contusion
12.4.6.2.3.4. Diffuse
Axonal Injury
12.4.6.2.3.5. Penetrating
Injury
12.4.6.2.3.6. Second
Impact Syndrome
12.4.6.2.3.7. Others
12.4.6.2.4. Others
12.4.7. Southeast
Asia
12.4.7.1. Southeast
Asia Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type
12.4.7.1.1. Anesthetics
12.4.7.1.2. Antagonists
12.4.7.1.3. Antibiotics
12.4.7.1.4. Antidepressants
12.4.7.1.5. Antiepileptic
agents
12.4.7.1.6. Anti-inflammatory
agents
12.4.7.1.7. Antioxidants/free
radical scavengers
12.4.7.1.8. Cytokines
12.4.7.1.9. Ion
Channel Blockers
12.4.7.1.10. Neurosteroids
12.4.7.1.11. Nutraceuticals
12.4.7.1.12. Pathway
Inhibitor
12.4.7.1.13. Others
(Vaccines, Toxins, etc.)
12.4.7.2. Southeast
Asia Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
12.4.7.2.1. Cerebrovascular
Disease
12.4.7.2.1.1. ischemic
stroke
12.4.7.2.1.2. hemorrhagic
stroke
12.4.7.2.1.3. cerebrovascular
anomalies
12.4.7.2.1.3.1. intracranial aneurysms
12.4.7.2.1.3.2. arteriovenous malformations
12.4.7.2.2. Neurodegenerative
Disorders
12.4.7.2.2.1. Alzheimer’s
Disease
12.4.7.2.2.2. Parkinson’s
Disease
12.4.7.2.2.3. Amyotrophic
Lateral Sclerosis
12.4.7.2.2.4. Progressive
supranuclear palsy (PSP)
12.4.7.2.2.5. Corticobasal
Degeneration (CBD)
12.4.7.2.2.6. Frontotemporal
Dementia (FTD)
12.4.7.2.2.7. Dementia
With Lewy Bodies (DLB)
12.4.7.2.2.8. Huntington’s
Disease (HD)
12.4.7.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
12.4.7.2.3. Traumatic
CNS Injuries
12.4.7.2.3.1. Coup-Contrecoup
Brain Injury
12.4.7.2.3.2. Concussion
12.4.7.2.3.3. Brain
Contusion
12.4.7.2.3.4. Diffuse
Axonal Injury
12.4.7.2.3.5. Penetrating
Injury
12.4.7.2.3.6. Second
Impact Syndrome
12.4.7.2.3.7. Others
12.4.7.2.4. Others
12.4.7.3. Southeast
Asia Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Country
12.4.7.3.1. Indonesia
12.4.7.3.2. Thailand
12.4.7.3.3. Malaysia
12.4.7.3.4. Singapore
12.4.7.3.5. Rest
of Southeast Asia
12.4.8. Rest of
Asia Pacific
12.4.8.1. Rest
of Asia Pacific Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By
Drugs Type
12.4.8.1.1. Anesthetics
12.4.8.1.2. Antagonists
12.4.8.1.3. Antibiotics
12.4.8.1.4. Antidepressants
12.4.8.1.5. Antiepileptic
agents
12.4.8.1.6. Anti-inflammatory
agents
12.4.8.1.7. Antioxidants/free
radical scavengers
12.4.8.1.8. Cytokines
12.4.8.1.9. Ion
Channel Blockers
12.4.8.1.10. Neurosteroids
12.4.8.1.11. Nutraceuticals
12.4.8.1.12. Pathway
Inhibitor
12.4.8.1.13. Others
(Vaccines, Toxins, etc.)
12.4.8.2. Rest
of Asia Pacific Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
12.4.8.2.1. Cerebrovascular
Disease
12.4.8.2.1.1. ischemic
stroke
12.4.8.2.1.2. hemorrhagic
stroke
12.4.8.2.1.3. cerebrovascular
anomalies
12.4.8.2.1.3.1. intracranial aneurysms
12.4.8.2.1.3.2. arteriovenous malformations
12.4.8.2.2. Neurodegenerative
Disorders
12.4.8.2.2.1. Alzheimer’s
Disease
12.4.8.2.2.2. Parkinson’s
Disease
12.4.8.2.2.3. Amyotrophic
Lateral Sclerosis
12.4.8.2.2.4. Progressive
supranuclear palsy (PSP)
12.4.8.2.2.5. Corticobasal
Degeneration (CBD)
12.4.8.2.2.6. Frontotemporal
Dementia (FTD)
12.4.8.2.2.7. Dementia
With Lewy Bodies (DLB)
12.4.8.2.2.8. Huntington’s
Disease (HD)
12.4.8.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
12.4.8.2.3. Traumatic
CNS Injuries
12.4.8.2.3.1. Coup-Contrecoup
Brain Injury
12.4.8.2.3.2. Concussion
12.4.8.2.3.3. Brain
Contusion
12.4.8.2.3.4. Diffuse
Axonal Injury
12.4.8.2.3.5. Penetrating
Injury
12.4.8.2.3.6. Second
Impact Syndrome
12.4.8.2.3.7. Others
12.4.8.2.4. Others
12.5. Key
Segment for Channeling Investments
12.5.1. By
Country
12.5.2. By
Drugs Type
12.5.3. By
Application
13. Middle East and Africa Neuroprotection Drugs Market Analysis
and Forecasts, 2019 - 2027
13.1. Overview
13.1.1. Middle
East and Africa Neuroprotection Drugs Market Revenue (US$ Mn)
13.2. Middle
East and Africa Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By
Drugs Type
13.2.1. Anesthetics
13.2.2. Antagonists
13.2.3. Antibiotics
13.2.4. Antidepressants
13.2.5. Antiepileptic
agents
13.2.6. Anti-inflammatory
agents
13.2.7. Antioxidants/free
radical scavengers
13.2.8. Cytokines
13.2.9. Ion
Channel Blockers
13.2.10. Neurosteroids
13.2.11. Nutraceuticals
13.2.12. Pathway
Inhibitor
13.2.13. Others
(Vaccines, Toxins, etc.)
13.3. Middle
East and Africa Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
13.3.1. Cerebrovascular
Disease
13.3.1.1. ischemic
stroke
13.3.1.2. hemorrhagic
stroke
13.3.1.3. cerebrovascular
anomalies
13.3.1.3.1. intracranial
aneurysms
13.3.1.3.2. arteriovenous
malformations
13.3.2. Neurodegenerative
Disorders
13.3.2.1. Alzheimer’s
Disease
13.3.2.2. Parkinson’s
Disease
13.3.2.3. Amyotrophic
Lateral Sclerosis
13.3.2.4. Progressive
supranuclear palsy (PSP)
13.3.2.5. Corticobasal
Degeneration (CBD)
13.3.2.6. Frontotemporal
Dementia (FTD)
13.3.2.7. Dementia
With Lewy Bodies (DLB)
13.3.2.8. Huntington’s
Disease (HD)
13.3.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
13.3.3. Traumatic
CNS Injuries
13.3.3.1. Coup-Contrecoup
Brain Injury
13.3.3.2. Concussion
13.3.3.3. Brain
Contusion
13.3.3.4. Diffuse
Axonal Injury
13.3.3.5. Penetrating
Injury
13.3.3.6. Second
Impact Syndrome
13.3.3.7. Others
13.3.4. Others
13.4. Middle
East and Africa Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By
Country
13.4.1. Saudi
Arabia
13.4.1.1. Saudi
Arabia Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs
Type
13.4.1.1.1. Anesthetics
13.4.1.1.2. Antagonists
13.4.1.1.3. Antibiotics
13.4.1.1.4. Antidepressants
13.4.1.1.5. Antiepileptic
agents
13.4.1.1.6. Anti-inflammatory
agents
13.4.1.1.7. Antioxidants/free
radical scavengers
13.4.1.1.8. Cytokines
13.4.1.1.9. Ion
Channel Blockers
13.4.1.1.10. Neurosteroids
13.4.1.1.11. Nutraceuticals
13.4.1.1.12. Pathway
Inhibitor
13.4.1.1.13. Others
(Vaccines, Toxins, etc.)
13.4.1.2. Saudi
Arabia Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
13.4.1.2.1. Cerebrovascular
Disease
13.4.1.2.1.1. ischemic
stroke
13.4.1.2.1.2. hemorrhagic
stroke
13.4.1.2.1.3. cerebrovascular
anomalies
13.4.1.2.1.3.1. intracranial aneurysms
13.4.1.2.1.3.2. arteriovenous malformations
13.4.1.2.2. Neurodegenerative
Disorders
13.4.1.2.2.1. Alzheimer’s
Disease
13.4.1.2.2.2. Parkinson’s
Disease
13.4.1.2.2.3. Amyotrophic
Lateral Sclerosis
13.4.1.2.2.4. Progressive
supranuclear palsy (PSP)
13.4.1.2.2.5. Corticobasal
Degeneration (CBD)
13.4.1.2.2.6. Frontotemporal
Dementia (FTD)
13.4.1.2.2.7. Dementia
With Lewy Bodies (DLB)
13.4.1.2.2.8. Huntington’s
Disease (HD)
13.4.1.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
13.4.1.2.3. Traumatic
CNS Injuries
13.4.1.2.3.1. Coup-Contrecoup
Brain Injury
13.4.1.2.3.2. Concussion
13.4.1.2.3.3. Brain
Contusion
13.4.1.2.3.4. Diffuse
Axonal Injury
13.4.1.2.3.5. Penetrating
Injury
13.4.1.2.3.6. Second
Impact Syndrome
13.4.1.2.3.7. Others
13.4.1.2.4. Others
13.4.2. UAE
13.4.2.1. UAE
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type
13.4.2.1.1. Anesthetics
13.4.2.1.2. Antagonists
13.4.2.1.3. Antibiotics
13.4.2.1.4. Antidepressants
13.4.2.1.5. Antiepileptic
agents
13.4.2.1.6. Anti-inflammatory
agents
13.4.2.1.7. Antioxidants/free
radical scavengers
13.4.2.1.8. Cytokines
13.4.2.1.9. Ion
Channel Blockers
13.4.2.1.10. Neurosteroids
13.4.2.1.11. Nutraceuticals
13.4.2.1.12. Pathway
Inhibitor
13.4.2.1.13. Others
(Vaccines, Toxins, etc.)
13.4.2.2. UAE
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application
13.4.2.2.1. Cerebrovascular
Disease
13.4.2.2.1.1. ischemic
stroke
13.4.2.2.1.2. hemorrhagic
stroke
13.4.2.2.1.3. cerebrovascular
anomalies
13.4.2.2.1.3.1. intracranial aneurysms
13.4.2.2.1.3.2. arteriovenous malformations
13.4.2.2.2. Neurodegenerative
Disorders
13.4.2.2.2.1. Alzheimer’s
Disease
13.4.2.2.2.2. Parkinson’s
Disease
13.4.2.2.2.3. Amyotrophic
Lateral Sclerosis
13.4.2.2.2.4. Progressive
supranuclear palsy (PSP)
13.4.2.2.2.5. Corticobasal
Degeneration (CBD)
13.4.2.2.2.6. Frontotemporal
Dementia (FTD)
13.4.2.2.2.7. Dementia
With Lewy Bodies (DLB)
13.4.2.2.2.8. Huntington’s
Disease (HD)
13.4.2.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
13.4.2.2.3. Traumatic
CNS Injuries
13.4.2.2.3.1. Coup-Contrecoup
Brain Injury
13.4.2.2.3.2. Concussion
13.4.2.2.3.3. Brain
Contusion
13.4.2.2.3.4. Diffuse
Axonal Injury
13.4.2.2.3.5. Penetrating
Injury
13.4.2.2.3.6. Second
Impact Syndrome
13.4.2.2.3.7. Others
13.4.2.2.4. Others
13.4.3. Egypt
13.4.3.1. Egypt
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type
13.4.3.1.1. Anesthetics
13.4.3.1.2. Antagonists
13.4.3.1.3. Antibiotics
13.4.3.1.4. Antidepressants
13.4.3.1.5. Antiepileptic
agents
13.4.3.1.6. Anti-inflammatory
agents
13.4.3.1.7. Antioxidants/free
radical scavengers
13.4.3.1.8. Cytokines
13.4.3.1.9. Ion
Channel Blockers
13.4.3.1.10. Neurosteroids
13.4.3.1.11. Nutraceuticals
13.4.3.1.12. Pathway
Inhibitor
13.4.3.1.13. Others
(Vaccines, Toxins, etc.)
13.4.3.2. Egypt
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application
13.4.3.2.1. Cerebrovascular
Disease
13.4.3.2.1.1. ischemic
stroke
13.4.3.2.1.2. hemorrhagic
stroke
13.4.3.2.1.3. cerebrovascular
anomalies
13.4.3.2.1.3.1. intracranial aneurysms
13.4.3.2.1.3.2. arteriovenous malformations
13.4.3.2.2. Neurodegenerative
Disorders
13.4.3.2.2.1. Alzheimer’s
Disease
13.4.3.2.2.2. Parkinson’s
Disease
13.4.3.2.2.3. Amyotrophic
Lateral Sclerosis
13.4.3.2.2.4. Progressive
supranuclear palsy (PSP)
13.4.3.2.2.5. Corticobasal
Degeneration (CBD)
13.4.3.2.2.6. Frontotemporal
Dementia (FTD)
13.4.3.2.2.7. Dementia
With Lewy Bodies (DLB)
13.4.3.2.2.8. Huntington’s
Disease (HD)
13.4.3.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
13.4.3.2.3. Traumatic
CNS Injuries
13.4.3.2.3.1. Coup-Contrecoup
Brain Injury
13.4.3.2.3.2. Concussion
13.4.3.2.3.3. Brain
Contusion
13.4.3.2.3.4. Diffuse
Axonal Injury
13.4.3.2.3.5. Penetrating
Injury
13.4.3.2.3.6. Second
Impact Syndrome
13.4.3.2.3.7. Others
13.4.3.2.4. Others
13.4.4. Kuwait
13.4.4.1. Kuwait
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type
13.4.4.1.1. Anesthetics
13.4.4.1.2. Antagonists
13.4.4.1.3. Antibiotics
13.4.4.1.4. Antidepressants
13.4.4.1.5. Antiepileptic
agents
13.4.4.1.6. Anti-inflammatory
agents
13.4.4.1.7. Antioxidants/free
radical scavengers
13.4.4.1.8. Cytokines
13.4.4.1.9. Ion
Channel Blockers
13.4.4.1.10. Neurosteroids
13.4.4.1.11. Nutraceuticals
13.4.4.1.12. Pathway
Inhibitor
13.4.4.1.13. Others
(Vaccines, Toxins, etc.)
13.4.4.2. Kuwait
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application
13.4.4.2.1. Cerebrovascular
Disease
13.4.4.2.1.1. ischemic
stroke
13.4.4.2.1.2. hemorrhagic
stroke
13.4.4.2.1.3. cerebrovascular
anomalies
13.4.4.2.1.3.1. intracranial aneurysms
13.4.4.2.1.3.2. arteriovenous malformations
13.4.4.2.2. Neurodegenerative
Disorders
13.4.4.2.2.1. Alzheimer’s
Disease
13.4.4.2.2.2. Parkinson’s
Disease
13.4.4.2.2.3. Amyotrophic
Lateral Sclerosis
13.4.4.2.2.4. Progressive
supranuclear palsy (PSP)
13.4.4.2.2.5. Corticobasal
Degeneration (CBD)
13.4.4.2.2.6. Frontotemporal
Dementia (FTD)
13.4.4.2.2.7. Dementia
With Lewy Bodies (DLB)
13.4.4.2.2.8. Huntington’s
Disease (HD)
13.4.4.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
13.4.4.2.3. Traumatic
CNS Injuries
13.4.4.2.3.1. Coup-Contrecoup
Brain Injury
13.4.4.2.3.2. Concussion
13.4.4.2.3.3. Brain
Contusion
13.4.4.2.3.4. Diffuse
Axonal Injury
13.4.4.2.3.5. Penetrating
Injury
13.4.4.2.3.6. Second
Impact Syndrome
13.4.4.2.3.7. Others
13.4.4.2.4. Others
13.4.5. South
Africa
13.4.5.1. South
Africa Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs
Type
13.4.5.1.1. Anesthetics
13.4.5.1.2. Antagonists
13.4.5.1.3. Antibiotics
13.4.5.1.4. Antidepressants
13.4.5.1.5. Antiepileptic
agents
13.4.5.1.6. Anti-inflammatory
agents
13.4.5.1.7. Antioxidants/free
radical scavengers
13.4.5.1.8. Cytokines
13.4.5.1.9. Ion
Channel Blockers
13.4.5.1.10. Neurosteroids
13.4.5.1.11. Nutraceuticals
13.4.5.1.12. Pathway
Inhibitor
13.4.5.1.13. Others
(Vaccines, Toxins, etc.)
13.4.5.2. South
Africa Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
13.4.5.2.1. Cerebrovascular
Disease
13.4.5.2.1.1. ischemic
stroke
13.4.5.2.1.2. hemorrhagic
stroke
13.4.5.2.1.3. cerebrovascular
anomalies
13.4.5.2.1.3.1. intracranial aneurysms
13.4.5.2.1.3.2. arteriovenous malformations
13.4.5.2.2. Neurodegenerative
Disorders
13.4.5.2.2.1. Alzheimer’s
Disease
13.4.5.2.2.2. Parkinson’s
Disease
13.4.5.2.2.3. Amyotrophic
Lateral Sclerosis
13.4.5.2.2.4. Progressive
supranuclear palsy (PSP)
13.4.5.2.2.5. Corticobasal
Degeneration (CBD)
13.4.5.2.2.6. Frontotemporal
Dementia (FTD)
13.4.5.2.2.7. Dementia
With Lewy Bodies (DLB)
13.4.5.2.2.8. Huntington’s
Disease (HD)
13.4.5.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
13.4.5.2.3. Traumatic
CNS Injuries
13.4.5.2.3.1. Coup-Contrecoup
Brain Injury
13.4.5.2.3.2. Concussion
13.4.5.2.3.3. Brain
Contusion
13.4.5.2.3.4. Diffuse
Axonal Injury
13.4.5.2.3.5. Penetrating
Injury
13.4.5.2.3.6. Second
Impact Syndrome
13.4.5.2.3.7. Others
13.4.5.2.4. Others
13.4.6. Rest of
Middle East & Africa
13.4.6.1. Rest
of Middle East & Africa Neuroprotection Drugs Market Revenue (US$ Mn) and
Forecasts, By Drugs Type
13.4.6.1.1. Anesthetics
13.4.6.1.2. Antagonists
13.4.6.1.3. Antibiotics
13.4.6.1.4. Antidepressants
13.4.6.1.5. Antiepileptic
agents
13.4.6.1.6. Anti-inflammatory
agents
13.4.6.1.7. Antioxidants/free
radical scavengers
13.4.6.1.8. Cytokines
13.4.6.1.9. Ion
Channel Blockers
13.4.6.1.10. Neurosteroids
13.4.6.1.11. Nutraceuticals
13.4.6.1.12. Pathway
Inhibitor
13.4.6.1.13. Others
(Vaccines, Toxins, etc.)
13.4.6.2. Rest
of Middle East & Africa Neuroprotection Drugs Market Revenue (US$ Mn) and
Forecasts, By Application
13.4.6.2.1. Cerebrovascular
Disease
13.4.6.2.1.1. ischemic
stroke
13.4.6.2.1.2. hemorrhagic
stroke
13.4.6.2.1.3. cerebrovascular
anomalies
13.4.6.2.1.3.1. intracranial aneurysms
13.4.6.2.1.3.2. arteriovenous malformations
13.4.6.2.2. Neurodegenerative
Disorders
13.4.6.2.2.1. Alzheimer’s
Disease
13.4.6.2.2.2. Parkinson’s
Disease
13.4.6.2.2.3. Amyotrophic
Lateral Sclerosis
13.4.6.2.2.4. Progressive
supranuclear palsy (PSP)
13.4.6.2.2.5. Corticobasal
Degeneration (CBD)
13.4.6.2.2.6. Frontotemporal
Dementia (FTD)
13.4.6.2.2.7. Dementia
With Lewy Bodies (DLB)
13.4.6.2.2.8. Huntington’s
Disease (HD)
13.4.6.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
13.4.6.2.3. Traumatic
CNS Injuries
13.4.6.2.3.1. Coup-Contrecoup
Brain Injury
13.4.6.2.3.2. Concussion
13.4.6.2.3.3. Brain
Contusion
13.4.6.2.3.4. Diffuse
Axonal Injury
13.4.6.2.3.5. Penetrating
Injury
13.4.6.2.3.6. Second
Impact Syndrome
13.4.6.2.3.7. Others
13.4.6.2.4. Others
13.5. Key
Segment for Channeling Investments
13.5.1. By
Country
13.5.2. By
Drugs Type
13.5.3. By
Application
14. Latin America Neuroprotection Drugs Market Analysis and
Forecasts, 2019 - 2027
14.1. Overview
14.1.1. Latin
America Neuroprotection Drugs Market Revenue (US$ Mn)
14.2. Latin
America Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs
Type
14.2.1. Anesthetics
14.2.2. Antagonists
14.2.3. Antibiotics
14.2.4. Antidepressants
14.2.5. Antiepileptic
agents
14.2.6. Anti-inflammatory
agents
14.2.7. Antioxidants/free
radical scavengers
14.2.8. Cytokines
14.2.9. Ion
Channel Blockers
14.2.10. Neurosteroids
14.2.11. Nutraceuticals
14.2.12. Pathway
Inhibitor
14.2.13. Others
(Vaccines, Toxins, etc.)
14.3. Latin
America Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By
Application
14.3.1. Cerebrovascular
Disease
14.3.1.1. ischemic
stroke
14.3.1.2. hemorrhagic
stroke
14.3.1.3. cerebrovascular
anomalies
14.3.1.3.1. intracranial
aneurysms
14.3.1.3.2. arteriovenous
malformations
14.3.2. Neurodegenerative
Disorders
14.3.2.1. Alzheimer’s
Disease
14.3.2.2. Parkinson’s
Disease
14.3.2.3. Amyotrophic
Lateral Sclerosis
14.3.2.4. Progressive
supranuclear palsy (PSP)
14.3.2.5. Corticobasal
Degeneration (CBD)
14.3.2.6. Frontotemporal
Dementia (FTD)
14.3.2.7. Dementia
With Lewy Bodies (DLB)
14.3.2.8. Huntington’s
Disease (HD)
14.3.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
14.3.3. Traumatic
CNS Injuries
14.3.3.1. Coup-Contrecoup
Brain Injury
14.3.3.2. Concussion
14.3.3.3. Brain
Contusion
14.3.3.4. Diffuse
Axonal Injury
14.3.3.5. Penetrating
Injury
14.3.3.6. Second
Impact Syndrome
14.3.3.7. Others
14.3.4. Others
14.4. Latin
America Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Country
14.4.1. Brazil
14.4.1.1. Brazil
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type
14.4.1.1.1. Anesthetics
14.4.1.1.2. Antagonists
14.4.1.1.3. Antibiotics
14.4.1.1.4. Antidepressants
14.4.1.1.5. Antiepileptic
agents
14.4.1.1.6. Anti-inflammatory
agents
14.4.1.1.7. Antioxidants/free
radical scavengers
14.4.1.1.8. Cytokines
14.4.1.1.9. Ion
Channel Blockers
14.4.1.1.10. Neurosteroids
14.4.1.1.11. Nutraceuticals
14.4.1.1.12. Pathway
Inhibitor
14.4.1.1.13. Others
(Vaccines, Toxins, etc.)
14.4.1.2. Brazil
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application
14.4.1.2.1. Cerebrovascular
Disease
14.4.1.2.1.1. ischemic
stroke
14.4.1.2.1.2. hemorrhagic
stroke
14.4.1.2.1.3. cerebrovascular
anomalies
14.4.1.2.1.3.1. intracranial aneurysms
14.4.1.2.1.3.2. arteriovenous malformations
14.4.1.2.2. Neurodegenerative
Disorders
14.4.1.2.2.1. Alzheimer’s
Disease
14.4.1.2.2.2. Parkinson’s
Disease
14.4.1.2.2.3. Amyotrophic
Lateral Sclerosis
14.4.1.2.2.4. Progressive
supranuclear palsy (PSP)
14.4.1.2.2.5. Corticobasal
Degeneration (CBD)
14.4.1.2.2.6. Frontotemporal
Dementia (FTD)
14.4.1.2.2.7. Dementia
With Lewy Bodies (DLB)
14.4.1.2.2.8. Huntington’s
Disease (HD)
14.4.1.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
14.4.1.2.3. Traumatic
CNS Injuries
14.4.1.2.3.1. Coup-Contrecoup
Brain Injury
14.4.1.2.3.2. Concussion
14.4.1.2.3.3. Brain
Contusion
14.4.1.2.3.4. Diffuse
Axonal Injury
14.4.1.2.3.5. Penetrating
Injury
14.4.1.2.3.6. Second
Impact Syndrome
14.4.1.2.3.7. Others
14.4.1.2.4. Others
14.4.2. Argentina
14.4.2.1. Argentina
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Drugs Type
14.4.2.1.1. Anesthetics
14.4.2.1.2. Antagonists
14.4.2.1.3. Antibiotics
14.4.2.1.4. Antidepressants
14.4.2.1.5. Antiepileptic
agents
14.4.2.1.6. Anti-inflammatory
agents
14.4.2.1.7. Antioxidants/free
radical scavengers
14.4.2.1.8. Cytokines
14.4.2.1.9. Ion
Channel Blockers
14.4.2.1.10. Neurosteroids
14.4.2.1.11. Nutraceuticals
14.4.2.1.12. Pathway
Inhibitor
14.4.2.1.13. Others
(Vaccines, Toxins, etc.)
14.4.2.2. Argentina
Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts, By Application
14.4.2.2.1. Cerebrovascular
Disease
14.4.2.2.1.1. ischemic
stroke
14.4.2.2.1.2. hemorrhagic
stroke
14.4.2.2.1.3. cerebrovascular
anomalies
14.4.2.2.1.3.1. intracranial aneurysms
14.4.2.2.1.3.2. arteriovenous malformations
14.4.2.2.2. Neurodegenerative
Disorders
14.4.2.2.2.1. Alzheimer’s
Disease
14.4.2.2.2.2. Parkinson’s
Disease
14.4.2.2.2.3. Amyotrophic
Lateral Sclerosis
14.4.2.2.2.4. Progressive
supranuclear palsy (PSP)
14.4.2.2.2.5. Corticobasal
Degeneration (CBD)
14.4.2.2.2.6. Frontotemporal
Dementia (FTD)
14.4.2.2.2.7. Dementia
With Lewy Bodies (DLB)
14.4.2.2.2.8. Huntington’s
Disease (HD)
14.4.2.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
14.4.2.2.3. Traumatic
CNS Injuries
14.4.2.2.3.1. Coup-Contrecoup
Brain Injury
14.4.2.2.3.2. Concussion
14.4.2.2.3.3. Brain
Contusion
14.4.2.2.3.4. Diffuse
Axonal Injury
14.4.2.2.3.5. Penetrating
Injury
14.4.2.2.3.6. Second
Impact Syndrome
14.4.2.2.3.7. Others
14.4.2.2.4. Others
14.4.3. Rest of
Latin America
14.4.3.1. Rest
of Latin America Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts,
By Drugs Type
14.4.3.1.1. Anesthetics
14.4.3.1.2. Antagonists
14.4.3.1.3. Antibiotics
14.4.3.1.4. Antidepressants
14.4.3.1.5. Antiepileptic
agents
14.4.3.1.6. Anti-inflammatory
agents
14.4.3.1.7. Antioxidants/free
radical scavengers
14.4.3.1.8. Cytokines
14.4.3.1.9. Ion
Channel Blockers
14.4.3.1.10. Neurosteroids
14.4.3.1.11. Nutraceuticals
14.4.3.1.12. Pathway
Inhibitor
14.4.3.1.13. Others
(Vaccines, Toxins, etc.)
14.4.3.2. Rest
of Latin America Neuroprotection Drugs Market Revenue (US$ Mn) and Forecasts,
By Application
14.4.3.2.1. Cerebrovascular
Disease
14.4.3.2.1.1. ischemic
stroke
14.4.3.2.1.2. hemorrhagic
stroke
14.4.3.2.1.3. cerebrovascular
anomalies
14.4.3.2.1.3.1. intracranial aneurysms
14.4.3.2.1.3.2. arteriovenous malformations
14.4.3.2.2. Neurodegenerative
Disorders
14.4.3.2.2.1. Alzheimer’s
Disease
14.4.3.2.2.2. Parkinson’s
Disease
14.4.3.2.2.3. Amyotrophic
Lateral Sclerosis
14.4.3.2.2.4. Progressive
supranuclear palsy (PSP)
14.4.3.2.2.5. Corticobasal
Degeneration (CBD)
14.4.3.2.2.6. Frontotemporal
Dementia (FTD)
14.4.3.2.2.7. Dementia
With Lewy Bodies (DLB)
14.4.3.2.2.8. Huntington’s
Disease (HD)
14.4.3.2.2.9. Others
(multiple system atrophy (MSA), chronic traumatic encephalopathy (CTE), etc.)
14.4.3.2.3. Traumatic
CNS Injuries
14.4.3.2.3.1. Coup-Contrecoup
Brain Injury
14.4.3.2.3.2. Concussion
14.4.3.2.3.3. Brain
Contusion
14.4.3.2.3.4. Diffuse
Axonal Injury
14.4.3.2.3.5. Penetrating
Injury
14.4.3.2.3.6. Second
Impact Syndrome
14.4.3.2.3.7. Others
14.4.3.2.4. Others
14.5. Key
Segment for Channeling Investments
14.5.1. By
Country
14.5.2. By
Drugs Type
14.5.3. By
Application
15. Competitive Benchmarking
15.1. Market
Share Analysis, 2018
15.2. Global
Presence and Growth Strategies
15.2.1. Mergers
and Acquisitions
15.2.2. Product
Launches
15.2.3. Investments
Trends
15.2.4. R&D
Initiatives
16. Player Profiles
16.1. AstraZeneca
16.1.1. Company
Details
16.1.2. Company
Overview
16.1.3. Product
Offerings
16.1.4. Key
Developments
16.1.5. Financial
Analysis
16.1.6. SWOT
Analysis
16.1.7. Business Strategies
16.2. Astrocyte Pharmaceuticals Inc.
16.2.1. Company
Details
16.2.2. Company
Overview
16.2.3. Product
Offerings
16.2.4. Key
Developments
16.2.5. Financial
Analysis
16.2.6. SWOT
Analysis
16.2.7. Business
Strategies
16.3. Biogen
16.3.1. Company
Details
16.3.2. Company
Overview
16.3.3. Product
Offerings
16.3.4. Key
Developments
16.3.5. Financial
Analysis
16.3.6. SWOT
Analysis
16.3.7. Business
Strategies
16.4. Bionure Farma, S.L.
16.4.1. Company
Details
16.4.2. Company
Overview
16.4.3. Product
Offerings
16.4.4. Key
Developments
16.4.5. Financial
Analysis
16.4.6. SWOT
Analysis
16.4.7. Business
Strategies
16.5. Genervon Biopharmaceuticals,
LLC.
16.5.1. Company
Details
16.5.2. Company
Overview
16.5.3. Product
Offerings
16.5.4. Key
Developments
16.5.5. Financial
Analysis
16.5.6. SWOT
Analysis
16.5.7. Business
Strategies
16.6. Hoffmann-La Roche Ltd
16.6.1. Company
Details
16.6.2. Company
Overview
16.6.3. Product
Offerings
16.6.4. Key
Developments
16.6.5. Financial
Analysis
16.6.6. SWOT
Analysis
16.6.7. Business
Strategies
16.7. Neuren Pharmaceuticals
16.7.1. Company
Details
16.7.2. Company
Overview
16.7.3. Product
Offerings
16.7.4. Key
Developments
16.7.5. Financial
Analysis
16.7.6. SWOT
Analysis
16.7.7. Business
Strategies
16.8. NeuroVive Pharmaceutical AB
16.8.1. Company
Details
16.8.2. Company
Overview
16.8.3. Product
Offerings
16.8.4. Key
Developments
16.8.5. Financial
Analysis
16.8.6. SWOT
Analysis
16.8.7. Business
Strategies
16.9. Novartis Pharmaceuticals
Corporation
16.9.1. Company
Details
16.9.2. Company
Overview
16.9.3. Product
Offerings
16.9.4. Key
Developments
16.9.5. Financial
Analysis
16.9.6. SWOT
Analysis
16.9.7. Business
Strategies
16.10. Teva Pharmaceutical Industries
Ltd
16.10.1. Company
Details
16.10.2. Company
Overview
16.10.3. Product
Offerings
16.10.4. Key
Developments
16.10.5. Financial
Analysis
16.10.6. SWOT
Analysis
16.10.7. Business Strategies
16.11. Other
Market Players
17. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.